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Genotyping arrays have greatly facilitated genetic epidemiological studies 
into genetic risk factors for numerous complex diseases such as psychiatric 
disorders. The use of genome-wide association analysis (GWAS) is 
unequivocally established. More recently, DNA methylation arrays have 
enabled genome-wide profiling of the methylome, in addition to 
contemporary genetic epidemiology study design. An example of one such 
study is the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) 
Lipidomics Study, which identified methylation markers (CpG markers) 
and single nucleotide polymorphisms (SNPs), associated with the change 
in triglyceride levels after drug intervention.  
Genotyping and methylation arrays assay several hundred thousand 
markers; however, single-marker association analysis suffers greatly from 
the burden of multiple testing. Set-based (SNP or CpG set) association 
approaches offer great flexibility, thus allowing the joint testing of a set of 
variants. For instance, a polygenic risk score (PRS) is a set-based approach, 
which, in addition to the strongly associated SNPs identified by large-scale 
GWAS, recruits SNPs with moderate to weak effects. The genotype 
information of the SNP set in the PRS is taken from an independent sample 
(target sample) and is then weighted by individual SNP effects derived 
from a relevant GWAS performed on a separate sample (discovery sample) 
into a cumulative score for each individual in the target sample. The 
resulting score, based on a SNP set or the PRS, is then regressed on the 
target phenotype. Such a regression model is evaluated by the amount of 
variance explained (R2) by the PRS in the target phenotype. Another 
strategy of set-based association analysis is kernel machine regression 
(KMR): a semi-parametric regression approach, in which the effects of 
markers within a set (CpG set or SNP set) are modelled via a kernel function 
and thus evaluated by a single-component variance test. A kernel function 
computes pairwise genomic similarity between the individuals, that is, the 
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inner product of a set of variants under analysis, maybe comprising a gene 
or a biological pathway. 
For my first article, I performed a simulation study to evaluate the 
performance of PRS in correlated discovery and target traits by considering 
various sample sizes of the target sample, namely n=200, 500, and 1000. The 
PRS for correlated traits can be viewed as a situation of calculating 
schizophrenia-PRS for psychosocial endophenotypes such as global 
assessment functioning (GAF) score or positive and negative syndrome 
scale (PANSS) score. Considering such a situation, I simulated four 
correlated target traits that had varying degrees of correlation (r2) with the 
discovery trait, i.e., r2= 1.00, 0.8, 0.6, and 0.4. The results demonstrated that 
the average R2 estimates by the PRS roughly decreased by the square of the 
correlation between the target traits. In addition, the range of estimated R2 
is most inflated in the sample size of the target trait n=200. Thus, the 
simulation findings alert researchers conducting clinical studies with 
endophenotypes to the fact that they need to pay attention to two important 
factors: first, the sample size of the target trait and secondly, the shared 
amount of genetic correlation between the target and discovery traits.  
In my second article, I implemented a KMR approach for set-based 
association testing of a CpG set. KMR has been successfully employed on 
SNP sets. In preparation of the second article, I used real and simulated 
datasets (based on a real dataset) provided by the Genetic Analysis 
Workshop 20 (GAW20) from the GOLDN study. GOLDN is a longitudinal 
study with individuals recruited from pedigrees. In my analysis, I only 
used independent individuals, which restricted the sample size in the real 
and simulated datasets to n<200. CpG sets were devised using the evidence 
of association reported by the GOLDN study in the real data set. For 
simulated datasets, true causal CpGs were provided by GAW20. Thus, I 
formulated candidate genomic regions of varying lengths while keeping 
the associated CpG(s) inside the region. The results replicated the evidence 
of association reported by GOLDN in the real data, and in simulated 
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datasets albeit nominally. Moreover, in the simulated data, causal SNPs 
exert their full effect on the phenoytpes given when the causal CpG loci had 
no methylation (B-value=0). Thus, I also considered modelling an 
interaction term along with the main effects. The results yielded significant 
association.  
As part of the discussion, simulation results on the performance of 
the linear kernel for a CpG set with original (B-values) and logit 
transformed methylation values (M-values) indicated that logit 
transformation results in a loss of power. There, I also considered analysing 
an additive kernel that combines the genotype kernel and the methylation 
kernel and then tests for association with the phenotype. The initial 
simulations suggest that an additive kernel with a CpG set including hypo, 
semi, and hypermethylated sites simultaneously might not improve the 
model over only including a SNP set. However, it appears fruitful to 
investigate further the situation in which only one type of methylation state 





1 INTRODUCTION ........................................................................................................... 1 
1.1 Association Analysis ....................................................................................... 4 
1.2 The Post GWAS -Era ........................................................................................ 7 
1.2.1 Set-based approaches for association analysis ..................................... 8 
1.2.2 DNA methylation: CpG sites................................................................ 10 
1.3 Objectives and Outline of Thesis ................................................................. 14 
2 METHODS .................................................................................................................. 15 
2.1 Model Notation .............................................................................................. 15 
2.2 Polygenic Risk Score Analysis ..................................................................... 17 
2.3 Kernel Machine Regression .......................................................................... 21 
2.3.1 Kernel function and association testing .............................................. 21 
3 SUMMARIES .............................................................................................................. 25 
3.1 PRS Approach in Correlated Phenotypes with Moderate to Small 
Sample Sizes ............................................................................................................... 25 
3.2 Kernel Machine Regression for DNA Methylation Data (CpG) and 
Modelling the Interaction Term between SNPs and CpG Variants .................... 28 
4 DISCUSSION .............................................................................................................. 32 
5 REFERENCES .............................................................................................................. 38 
6 APPENDIX .................................................................................................................. 46 
I. References, Web-Links and Digital Object Identifiers of Original 










The completion of the Human Genome Project in 2003 enabled researchers 
to search extensively for genetic loci responsible for diseases such as type 2 
diabetes mellitus (T2DM), coronary artery disease (CAD), cancer, and 
psychiatric disorders [1]. Since 2003, there have been extensive advances in 
numerous molecular techniques, from the first-generation DNA 
sequencing using Sanger’s method to massively parallel sequencing 
technologies enabling rapid sequencing of the whole genome. The 
application of these new technologies led to a considerable amount of 
development in statistical genetics methods. Thus, a key focus of genetic 
research has been to identify the molecular aberrations that make humans 
more susceptible to disease or a more severe disease course, and to explain 
the genetic architecture of a disease (or a phenotype).  
The molecular aetiology of diseases is complex; in addition to 
genetics, numerous other factors such as epigenetics and the environment 
also play some role in the susceptibility, development, and progression of 
diseases [2]. Various classifications of disease exist; for instance the number 
of genes causing and/or influencing a disease is one of the common 
methods to classify diseases, as in the terms monogenic – a single gene; 
oligogenic – a few genes; and polygenic – several to many genes [3]. 
Another classification bases on the disease prevalence in populations, i.e., 
the number of affected individuals in a population for a particular disease 





Existing evidence suggests that most rare diseases exhibit a 
Mendelian pattern of inheritance, an example of which being maturity-
onset diabetes of the young (MODY), which displays autosomal 
dominant inheritance [5]. Mendelian diseases are rare in population, i.e., 
in a sample of unrelated individuals with European ancestry, the 
proportion of affected individuals carrying the pathogenic variant(s) is 
small-this is also defined as penetrance. However, this is otherwise for a 
sample comprised of related individuals such as those belonging to a 
pedigree. In a pedigree, the penetrance of Mendelian diseases is high or 
even complete i.e., all individuals that inherited pathogenic variant(s) 
exhibit disease. This hints towards searching for chromosomal segment(s) 
harbouring disease-causing mutation(s) that tend to be localised within a 
pedigree owing to co-segregation. Thus, mapping of such loci has been very 
fruitful via linkage analysis, which is a statistical genetics method of 
locating chromosomal segments that co-segregate with the disease 
phenotype through families [6].  
To date, the loci for almost 6,800 phenotypes have been successfully 
mapped using linkage analysis [7], for instance CFTR for cystic fibrosis, 
HNF1α for maturity-onset diabetes of the young (MODY), and BRCA1 
and BRCA2 for breast cancer [8]. However, an important fact is that 
localization of co-segregated genomic regions with disease causing 
mutation(s) for individuals belonging to a pedigree does not necessarily 
mean that all such individuals will exhibit the disease, this is also referred 
to as reduced or incomplete penetrance. Incomplete penetrance has been 
observed in the pedigree studies for breast cancer i.e., individuals albeit 
carrying pathogenic mutations in BRCA1 and BRCA2 do not have breast 
cancer [8]. 
On other hand, the majority of common diseases exhibit a complex 
polygenic architecture, that is, an intricate interplay between several to 





human genome [6]. The pattern of inheritance of these loci is not yet fully 
understood. Indeed, they seem to influence disease aetiology by 
interrupting multiple biological pathways and gene regulatory networks 
[3, 6]. One well-studied example of such a complex disease aetiology is 
diabetes mellitus - a highly heterogeneous group of diseases exhibiting 
different pathophysiology with hypoglycaemia as a common feature [5]. 
The identification of the genes behind MODY encouraged and accelerated 
the genetic studies into T2DM, the more prevalent diabetic phenotype [9]. 
Using pedigree-based study designs, genome-wide linkage analysis 
revealed an initial set of loci at PPARG, KCNJ11, and near TCF7L2 for T2DM 
[5]. The linkage‐based analysis for T2DM was not particularly fruitful; the 
acceleration in risk‐variant discovery for T2DM has been primarily driven 
by the introduction of genome-wide association studies (GWASs). By 
definition, a GWAS is a statistical approach that scans genetic variants, 
genotyped on a commercial array for a number of unrelated individuals 
sampled from a population, to find statistical evidence of genetic variations 
associated with a particular disease. The first round of findings from the 
GWASs for T2DM confirmed evidence of strong association (odds ratio 
(OR) > 4.0) for previously identified loci through linkage analysis. In 
addition, it revealed a set of novel loci with modest to weak signals (OR 
approximately 1.05–1.35) near CDKAL1, HHEX, SLC30A8, IGF2BP2, and 
CDKN2A [5]. Nevertheless, the contributions made by pedigree-based 
study designs are unprecedented in both rare as well as common diseases.  
Another well-known example of a common disease is CAD, for 
which genome-wide linkage analysis also unravelled an initial set of 
genetic variants, in a similar fashion to T2DM. For instance, a genome-wide 
linkage analysis conducted on the U.S GeneQuest cohort with 428 nuclear 
families identified six novel loci on chromosomes 3p25.1, 3p29, 9q22.3, 
9p34.11, 17p12, and 21q22.3 [10]. Also for CAD, another genome-wide 





chromosomes 2q21.1–22 and Xq23–26 [11]. Thus, genome-wide linkage 
analysis enabled the discovery of only a handful of variants (with strong 
effect sizes) for common diseases with a polygenic architecture [12].  
With the increasing amount of evidence furnished by the GWASs it 
became clearer that polygenic diseases are driven by several to many 
genetic variants with modest-to-weak effect sizes and minor allele 
frequencies (MAFs) >1% (also called common variants). These common 
variants do not necessarily cause the disease but rather influence the risk of 
developing the disease [13].  
Along with the polygenic and highly multifactorial nature, the diagnosis of 
one common disease might also confer genetic predisposition to 
developing another distinct disease.  For instance, patients with T2DM are 
at a higher risk of developing CAD than are non-T2DM patients - hinting 
towards a shared set of genetic variants in both distinct disease aetiologies. 
Results from a large-scale GWAS for T2DM and CAD has also shown a 
strong evidence of shared genetic correlation in both diseases i.e., genetic 
variants associated with increased risk of CAD are also associated with 
increased risk of T2DM [1, 14].  
1.1 Association Analysis 
Association determines whether a particular allele or genotype in a 
population is associated with the disease more often than expected by 
chance. Those positions in the DNA sequence displaying an exchange of a 
single nucleotide are called single nucleotide polymorphisms (SNPs). Let 
the alleles be denoted by A, and a, so that the individual genotype at any 
bi-allelic SNP site is AA, Aa, or aa.  
In statistical modelling, in a traditional GWAS, the most common 
outcome of interest is either a quantitative measure of phenotype such as 





(yes/no), and the features (or variables) are several hundred thousands or 
millions of genotyped or imputed SNPs. The standard approach to 
analysing a GWAS is based on testing each genotyped SNP in the genome 
individually for statistical significance of its association with the phenotype 
under investigation. Logistic regression is employed for a binary 
phenotype and linear regression for a quantitative phenotype [15]. The first 
GWAS in 2005 on 100K genotyped SNPs with a sample size of 146 
individuals gave robust evidence of association for complement factor H 
(CFH) with age-related macular degeneration with an Odds Ratio (OR) of 
4.6 [15]. Later on in 2007, the explosion in GWAS analyses revealed that the 
majority of common risk alleles conferred effect sizes of < 1.5 OR [15]. 
It is estimated that a typical human genome differs from the 
reference human genome at 4.1 million to 5.0 million sites [16]. The latest 
information available at the 1000 Human Genomic Consortium project 
website for the phase 3 reports 84.4 million variants in  n= 2504 individuals 
from 26 populations [17]. Nevertheless, SNP arrays genotype far less 
variants. This can be explained by the phenomenon of linkage 
disequilibrium (LD). In a sample of individuals from a population with a 
common genetic ancestry such as European, alleles in two SNPs that are 
physically close to each other appear together more often than would be 
expected by chance , thus these two SNPs are said to be in LD with each 
other [18]. Mathematically, the LD between two genetic variants can be 
quantified as a correlation between SNPs across a population. Two SNPs 
that are in strong LD can serve as proxies for one another [19, 6]. That is, if 
the correlation between the two SNPs is high, genotyping one of these 
provides almost complete genotype information of another. Therefore, a 
SNP array that genotypes ~1 million SNPs can effectively assay a larger 
proportion of the human genome [19]. However, the issue of array coverage 
also needs to be considered while performing the quality control and 





commercial genotyping arrays have been specifically designed to genotype 
SNPs that correlate with, or ‘tag/represent’, a large number of other SNPs 
in the human genome [19].  
Over the last years, GWASs have made major contributions to the 
efforts of gene mapping by identifying numerous novel genetic 
associations. However, early studies had small sample sizes [15] and were 
thus underpowered to detect the small effect sizes expected for the common 
variants, hinting that these variants require large sample sizes. Hence, 
meta-analysis of available GWAS data from different studies was soon 
recognized as an appropriate method in order to achieve adequate sample 
sizes and the optimum power to discover genetic associations with modest 
to weak effect sizes [20]. For instance, a meta-analysis GWAS of T2DM, with 
~16 million genetic variants in 62,892 cases and 596,424 controls identified 
143 SNPs [21]. This approach led to the establishment of disease-specific 
consortia such as the Psychiatric GWAS Consortium (PGC), the Cognitive 
Genomics Consortium (COGENT), and the Genetic Investigation of 
ANthropometric Traits Consortium (GIANT).  
Undoubtedly, the contribution of GWASs to a better understanding of 
complex diseases is unprecedented, but it does suffer several limitations. 
The following are some of the key limitations of GWAS:  
1. High dimensionality – Multiple testing problem  
A large sample size for performing a GWAS is necessary because it 
essentially requires testing hundreds of thousands of SNPs (high 
dimensionality of the data), resulting in hundreds of thousands of tests (the 
multiple testing problem). As a result, GWASs are underpowered to detect 
a major part of the genetic variance in a phenotype that might be explained 
by SNPs, which do not achieve the required significance level owing to 
multiple testing correction. The fraction of total variance (V) determined by 





genetics, an additive model of heritability is often assumed, simply 
summing the contributions of all the additive alleles influencing that trait 
[22].  
2. LD hinders pinpointing the causal variants  
Local correlation between SNPs in LD facilitates the initial identification 
of a locus i.e., genomic region but makes it difficult to discern the causal 
variant(s). Most GWAS-identified association signals so far map to non-
coding regions of the genome [22], for which any biological interpretation 
is inherently challenging.  
3. Missing Heritability: A post-GWAS challenge  
The variance (V) of a phenotype can be sub-divided as a sum of two 
components, one part explained by genetics (heritability) and the other 
explained by environmental or other unknown factors. Given the polygenic 
architecture of complex diseases and unknown patterns of Mendelian 
inheritance, we assume an additive model of genetics for polygenic 
diseases; all genetic factors contribute towards VG in an additive fashion. 
Although evidence of a non-additive model of genetics (or heritability) is 
difficult to assess in humans, model organisms (for example, yeast, worm, 
fly, or mouse) have established epistasis as a pivotal component of the 
genetic architecture of complex traits [22, 23]. However, the identification 
of significant gene–gene interactions has been challenging in GWAS and 
post-GWAS experiments in humans, owing primarily to a lack of statistical 
power and to methodological challenges.  
1.2 The Post GWAS -Era  
In order to enhance our existing understanding of molecular 
underpinnings behind complex diseases, in addition to genetic variations, 
geneticists have investigated various other -omic or molecular processes 





reversible attachment of a chemical cap that does not change the DNA 
sequence such as the addition of a functional group (methyl) or a protein 
(histone) to the DNA sequence [23]. These events control various molecular 
processes such as regulation of the transcriptional state of a gene, i.e. gene 
activation or gene silencing. In other words, it controls the production of 
the functional form of gene(s). Thus, epigenetic processes have also been 
exploited as biological markers for disease characterization. For example, 
in cancer, the over-expression of gene(s) is suspected as a function of 
observed high levels of DNA methylation (DNAm) in the blood sample. 
DNAm refers to the reversible addition of a methyl group to cytosine-
guanine dinucleotide (CpG) sites in the DNA sequence. In parallel to the 
progress made by molecular techniques, numerous statistical methods 
have been developed to address the computational limitations of GWAS 
such as set-based approaches for association analysis.  
1.2.1 Set-based approaches for association analysis 
The GWAS design suffers from the curse of high dimensionality of the data, 
strong LD between variants, and multiple weakly associated variants, 
while set-based approaches allow joint testing of a subset of variants from 
the total set of genotyped variants, greatly reducing dimensions of the data 
[22].   
Several methods have been proposed to combine SNPs in a set. One 
such method is to use the genomic annotation and/or genomic features of 
SNPs and then mapping these to a gene or multiple genes(s) involved in 
biological pathway(s) [13]. Another strategy is to exploit the statistical 
evidence of association obtained through GWAS analysis of SNPs such as 
p-value and thus partitioning the genome-wide SNPs into several subsets 
of SNPs ranked by their p-values. The joint analysis of several SNPs together 
not only yields improved power in settings where SNPs individually have 





testing (Single marker analysis in the GWAS design). In addition, tag SNPs 
are in LD with causal loci and thus a set-based approach allows testing the 
association of a batch of biologically important SNPs with the phenotype 
[24], instead of an individual SNP. Many GWASs may not release 
individual-level data owing to logistic challenges or data confidentiality 
agreements. Instead, it is much more likely that a marginal test statistic for 
association with the outcome is available for each individual SNP. The 
individual SNP association estimates for numerous complex phenotypes 
such as schizophrenia (SZ), major depression disorder (MDD), and autism 
are publically accessible. These statistical estimates from large consortia 
have been used as weights to aggregate the genome-wide genotype SNPs 
for an individual into a single value estimate, named the polygenic risk 
score (PRS). PRS can be viewed as a set-based approach, which initially 
recruits all genotyped SNPs whose association estimates are available. Let 
us assume the set with all genotyped SNPs is a superset M. In the next steps, 
several proper subsets of SNPs from the set M are formulated, ranked by 
the p-values of single SNPs. S is a proper subset of M, if there is at least one 
element of M that is not an element of S. Moreover, all the elements in these 
proper subsets are necessarily members of the superset M. From these 
several proper subsets of SNPs, several PRSs are then constructed. Each 
PRS is then associated with the phenotype of interest and through several 
regressions, the optimal PRS is selected, which is actually constructed on a 
subset of SNPs (more details in the methods chapter). 
Building the additive, albeit weighted sum of additive genetic 
heritability is the most commonly exploited model, as it allows parametric 
modelling based on linear regression. However, this model is indeed an 
oversimplification for polygenic diseases. Therefore, a hybrid regression 
approach called kernel machine regression (KMR) is proposed. In KMR 
covariates such as age, gender, and smoking status are modelled 





non-parametrically. More specifically, the non-parametric effect of multiple 
markers is modelled via a kernel (more details in the methods chapter). The 
KMR framework has shown to be robust as it allows great flexibility in the 
functional relationship between the SNPs belonging to a set and the disease 
or the outcome of interest. Numerous kernels exist, such as the linear 
kernel, Gaussian kernel, and quadratic kernel. For genetic variants, the 
linear kernel has been successfully employed in association testing [25].  
1.2.2 DNA methylation: CpG sites  
A big challenge after GWAS is to explain the functions of the identified 
SNPs, and to illustrate the mechanisms underlying the associations. The 
current GWAS catalog stats released on 04th April 2021, hosts data for 
158,358 SNPs with 255,015 associations from 5002 GWAS publications [26]. 
Most of these associated SNPs are located in the non-coding region of DNA, 
which might be the genomic regions harbouring the transcriptional 
machinery of gene(s) such as promoters, enhancers, or silencers [27].  
DNAm is a reversible-dynamic epigenetic event; thus, the degree of 
methylation at a CpG site or several closely located CpG sites of DNA 
determines the transcriptional state of nearby gene(s) [28, 29, 30]. For 
instance, hypo-methylation of a DNA sequence in a promoter triggers gene 
activation while hyper-methylation signals gene silencing [28, 29]. 
According to the ENCODE database, the human genome has 
approximately 28 million CpG sites that exhibit varying methylation 
patterns [31]. Similar to genotyping arrays, Illumina also provides DNAm 
arrays, namely the Illumina Human Methylation 450 K (also 850K: K refers 
to 1000 i.e., 1K=1000 sites) and Infinium Methylation EPIC (EPIC) 
BeadChips (Illumina Inc, San Diego, CA) [32]. These arrays have limited 
coverage of the methylome and can only detect up to 870K CpGs across the 
human epigenome, leaving a large proportion of CpG sites unmeasured. 





change over time [28]. DNAm via arrays is usually profiled in the whole 
blood samples. Whole blood contains several cells of distinct types in 
various proportions; this is one of the prominent confounding factors of 
DNAm data generated from arrays. Analogous to the whole-genome 
sequencing technique of DNA, DNAm profiling can also be done at single-
base-pair resolution using the whole-genome bisulphite technique, but is 
expensive. In the whole-genome bisulphite technique, DNAm is profiled in 
the cell lines.  
The DNAm level of a CpG site is a beta-distributed continuous value 
varying from 0 to 1. At each CpG site, methylation is quantified by the beta 
value, denoted as: 
B-value: = M / (M + U + a), 
where M > 0 and U > 0 denote the methylated and unmethylated signal 
intensities [33, 34]. The offset a ≥ 0 is usually set equal to 100 and is added 
to M+U to stabilize beta values when both M and U are small [34]. The 
distribution of an individual CpG site across various individuals can be 
considered as beta-distributed with values bounded between zero and one 
[33]. If the methylation of a site is zero, it refers to a state of no methylation, 
a biological indicator of transcriptional activity; and a value of one is 
maximum methylation, a biological indicator of minimum or no 
transcriptional activity. In practice, the methylation state of a CpG site 
depending upon the corresponding measured B-value of DNAm belongs to 
one of the three classes, i.e., hypo-methylated (B-value <0.20), semi-
methylated (B-value >0.20 and <0.70), or hyper-methylated (B-value >0.70) 
[35]. Gaussian regression with the beta-distributed B-values of DNAm data 
is problematic. The variance of B-values is usually smaller near the 
boundaries than the middle of the interval (0 (, 1), implying violation of the 
homoscedasticity assumption required in Gaussian regression [35]. To 





including Gaussian regression with logit-transformed B-values, called M-
values, and generalized regression models incorporating B-values as 
responses, e.g. beta regression.  
In addition, alike GWASs epigenome-wide association studies 
(EWAS) analyses have been conducted to study the disrupted genome-
wide patterns of DNAm for numerous diseases such as for metabolic 
syndrome, schizophrenia, and inflammatory or autoimmune disorders 
[35]. For EWAS analysis, an identical approach to the traditional GWAS has 
been used, which also suffers from similar limiting factors.  Moreover, 
recent studies have demonstrated evidence for loci harbouring SNPs that 
influence the methylation state [31]. Such loci have been termed 
methylation quantitative trait loci (methQTLs). In most methQTL, the 
correlations with the nearby genotypes (cis-genotype: on same DNA 
strand) are most pronounced. There is some evidence that SNPs can also 
influence methylation state(s) of CpG site(s) in trans (located on another 
strand of DNA), but this does not seem to be as prevalent as cis-effects. It is 
also important to note that in most of these previous studies, the true 
causative SNP was not identified unequivocally [22]. In some cases, 
disease-associated epigenetic variation could arise prior to disease onset, 
but still not be causative for the disease [23]. This type of epi-phenomenon 
could be a result of confounding, when an environmental factor such as 
smoking, or a genetic variant, induces both aberrant epigenetic states and 
disease. These potential relationships between epigenetic variation and 
complex disease have important implications for the design and analysis of 
EWAS [30]. There are several EWAS designs being opted, such as 
monozygotic twins, and longitudinal cohorts [35]. In addition to single 
marker association analysis, EWAS has also been employed in the 
elucidation of the drug response by recording pre and post-treatment 





More recently along with GWAS, researchers have started performing 
EWAS on the same individuals along with considering the gene expression 
datasets as well. These datasets have enabled integrated analysis of 
multiple layers of omics data for the phenotype of interest with the aim of 
improving our existing understanding of disease. One of the noticeable 
examples is the integration of the gene expression data from blood 
(n = 14,115 and 2765) with the GWAS results for T2DM, which identified 33 
putative functional genes, three of which were targeted by approved drugs 
[21]. A further integration of DNAm (n = 1980) and epigenomic annotation 
data highlighted three genes (CAMK1D, TP53INP1, and ATP5G1) with 
plausible regulatory mechanisms, whereby a genetic variant exerted an 





1.3 Objectives and Outline of Thesis 
The main objective of the research work done for this thesis is an evaluation 
of the set-based association approaches. Two statistical approaches are part 
of this thesis; one is a purely parametric regression approach: the polygenic 
risk score. The other approach is semi-parametric in nature and is named 
kernel machine regression. The research towards this thesis aims to 
enhance the existing understanding of both methods through an extensive 
simulation study and by using other omics data (epigenetic data: DNA 
methylation) with and without considering the interaction between genetic 
and epigenetic data. For the PRS method, I performed extensive 
simulations with varying sample sizes (small to moderate as is common in 
clinical studies). In addition, I evaluated the performance of PRS for 
correlated complex phenotypes instead of only using identical or similar 
phenotype. The KMR method has been exploited fairly well for SNP sets.  
In this thesis, my focus was to review the performance of the kernel for CpG 
markers. In addition, I also considered modelling an interaction term 










2.1 Model Notation 
Let us suppose we have genotyped m SNPs for n individuals, for which we 
measured a quantitative, normally distributed phenotype y. A traditional 
GWAS analysis proceeds by sequentially testing the null hypothesis of no 
association between the SNP and the phenotype for each single SNP [36, 
37]. For a bi-allelic SNP with alleles denoted as A and a, there are various 
genotype-coding methods for the three possible genotypes i.e., AA, Aa, and 
aa. I will use the count of minor alleles in a genotype. Let us assume allele 
a is the minor allele, thus 0 for genotype AA, 1 for Aa, and 2 for aa. In GWAS 
analysis, an additive model is assumed, which implies that if the risk 
conferred by the minor allele a increases by r-fold for the heterozygous 
genotype (Aa) then it increases 2r-fold for the homozygous genotype (aa) 
[38]. 
The linear regression model in a typical GWAS for a quantitative 
outcome for an individual i is as follows: 
𝑦𝑖 =  𝑥𝑖
𝑇𝛽 +  𝛽𝑞𝑔𝑖𝑞 + 𝜀𝑖 ;      𝜀𝑖~
𝑖.𝑖.𝑑𝒩(0, 𝜎2)                   Eq. 2.1 
where 𝑔𝑖𝑞  denotes the minor allele count for qth SNP;  𝑞 =1,…,m  in 
the ith individual;  i =1,…,n , and 𝛽𝑞 is the regression coefficient for the qth 
SNP. 𝑥𝑖
𝑇 denotes the transposed (𝑇) vector of considered covariates, such as 
age, gender, and/or smoking status including the intercept; 𝛽𝑥 denotes the 





terms, which are  identically independently  distributed (i.i.d.) and follow 
a normal distribution. We consider a test for no association between the 
genotype 𝑔𝑖𝑞  and outcome 𝑦𝑖 , i.e., 𝛽𝑞 = 0 as given in Eq. 2.1. Given m 
genotyped SNPs, m linear regression models are performed for a traditional 
GWAS. Thus, for the qth SNP, the fitted regression model estimates the 
regression coefficient ?̂?𝒒; this is also called the estimated effect size. In 
addition, the fitted regression model also provides association statistics for 
the estimated effect size ?̂?𝒒, which includes the standard error (SE) of the 
estimated effect ?̂?𝒒, and the p-value for the qth SNP with the outcome 𝑦𝑖. If 
the p-value for ?̂?𝒒 is less than the defined level of significance α, the null 
hypothesis can be rejected. The commonly used alpha values are 0.01 and 
0.05. However, in a GWAS for m genotyped SNPs, m regression analyses 
are performed, i.e. simultaneously testing m null hypotheses of no 
association between the genotypes of m SNPs and the phenotype 𝑦, for n 
individuals. Thus, the individual p-values for the m SNPs need to be 
corrected for multiple testing. A commonly used method for multiple-
comparison correction is the Bonferroni correction; other methods include 
the Tukey-Kramer and Scheffe method [39, 40]. The Bonferroni correction 
is a conservative multiple-comparison correction method that resets the 
alpha value (α =0.05) for the m regression tests to 𝛼/𝑚 and thus the 
signficance level for the estimated p-value is adjusted for multiple tests. For 
GWAS analysis, the proposed genome-wide significance level is 5 × 10−8 
[39]. 
The association statistics for the m tested SNPs altogether are termed 
summary statistics of a GWAS analysis. In a typical summary statistics 
report of a GWAS analysis, each line represents the association statistic 𝐴𝑞 
for the qth SNP, such that 𝐴𝑞 = {?̂?𝑞, 𝑆𝐸𝑞 , 𝑝 − 𝑣𝑎𝑙𝑢𝑒𝑞}. Along with the 
association statistics, other information such as the genomic location of 
SNPs is also given. These summary statistics reports are publicly available 





2.2 Polygenic Risk Score Analysis 
The main goal of GWASs so far has been to identify causal variants that tell 
us about the biology of the phenotype and propose ways for targeted 
treatments [22, 36, 41]. GWAS findings have unravelled robust statistical 
association evidence for quite a number of loci, albeit the number of 
statistically significant SNPs is small and the effects are far from explaining 
the missing heritability [6, 22]. Even though many SNPs with weak to 
moderate effects can be assumed as associated to phenotypes however, a 
wide majority of loci do not achieve any genome-wide significance level 
owing to the multiple testing burden [22, 37, 41].  
A polygenic risk score (PRS) is an individual-level score of genetic 
risk, which can be conceptualised as an aggregate measure of allelic counts 
across a set of genetic variants weighted by effect sizes, derived from an 
appropriate GWAS result [42, 43]. Initially, PRS computation was restricted 
to SNPs that reached genome-wide significance [42]. However, with the 
availability of GWAS results from much larger studies such as those from 
consortia, PRS also included SNPs that did not reach genome-wide 
significance [43, 44, 45, 46, 47].  
In principle, the computation of PRS requires two main ingredients: 
First a sample of independent individuals with genotype and phenotype 
information for a complex trait/disease - the so-called target trait. Secondly, 
an appropriate GWAS summary statistic estimated in an independent 
sample with identical or correlated phenotype to that of the target trait is 
needed. This phenotype is termed the discovery phenotype. Usually the 
sample size of GWAS for the discovery phenotype is quiet large in 
comparison to the target trait. Let us suppose a SNP set R, which is a proper 
subset of SNP set M. Here SNP set M refers to the m genotyped SNPs for 
the target trait. For simplicity, we assume the GWAS summary statistics 





set R has 𝑟 SNPs. G is then an 𝑛 × 𝑟 matrix, which has genotype information 
for the r  SNPs and 𝑛 individuals in the target sample. Each element of the 
matrix G, denoted as 𝑔𝑖𝑞 is the genotype information (0, 1, or 2) for the qth 
SNP, q=1, …,r , in the  ith individual i=1, …,n.  ?̂?𝑞 is the  genetic effect size 
estimated for  a single SNP in an external large-scale GWAS of a discovery 
trait. Thus, PRS for the individual 𝑖 can be computed as follows:  
𝑃𝑅𝑆𝑖 =  ∑ ?̂?𝑞𝐺𝑖𝑞
𝑟
𝑞=1              Eq. 2.2 
PRSi is the cumulative sum of minor allele counts of genotypes across the r  
SNPs, weighted by the respective estimated effect of the SNPs [42]. The 
GWAS summary statistics for the discovery trait are usually estimated on a 
very large sample size, such as several thousand individuals, and are 
publicly accessible. For instance, at the Psychiatric Genomic Consortium 
(PGC) for schizophrenia, performed a GWAS analysis on 36,989 cases and 
113,075 controls with European ancestry, and published the GWAS 
summary statistics [44].  
PRS analysis can be viewed as a search of the SNP set R, such that 𝑅 ⊂
𝑀. In order to find the SNP set R, several subsets of SNP set M are 
formulated. Prior to sub-setting the SNP set M, preliminary SNP filtering is 
recommended to address problems such as multicollinearity. Thus, SNP 
filtering followed by the sub-setting of SNP set M is a two-stepped 
approach. The first step is clumping, which removes correlated SNPs from 
the SNP-set M; the resulting SNP set is denoted as Mclumped, followed by the 
second step of sub-setting SNPs in the SNP set Mclumped, using a 
thresholding-based criterion. This approach is called clumping and 
thresholding (C+T), sometimes also known as pruning and thresholding 
(P+T). 
In the first step, clumping (C) is performed such that SNPs in set M, 





multicollinearity among SNPs [45]. Clumping selects the most significant 
SNPs iteratively by computing the correlation (𝑟2) between an index SNP 
and its nearby SNPs within a window based on genetic distance between 
SNPs [43]. This removes the nearby SNPs that demonstrate greater 
correlation with the index SNP beyond a given threshold [45]. The 
recommended threshold is 𝑟2 = 0.8, which we also used in our analysis 
[43]. The clumping step prunes redundant correlated effects caused by 
linkage disequilibrium (LD) between SNPs [43]. For clumping, keeping in 
consideration the LD pattern in the human genome, a window size between 
250 kbp to 500 kbp is recommended [43, 46]. However, this procedure may 
also remove independently predictive SNP(s) that are in LD with the index 
SNP.  
The second step is thresholding (T). The GWAS summary statistics 
of SNPs in SNP-set Mclumped obtained from the discovery sample are ranked 
from lowest to highest p-value [43]. Let us suppose a vector S of length s 
comprises of positive real numbers ranging between 0 and 1. Each element 
in the vector S represents the discrete p-value grid points deployed as the p-
value threshold to create s number of proper SNP subsets from the SNP set 
Mclumped. Each subsequent SNP set which is subset of SNP set Mclumped, 
necessarily incorporates cumulatively SNPs from the previous p-
value threshold. That is, SNPs at the 0.001 p-value threshold are a proper 
subset of SNPs at the p-value threshold of 0.01. 
In this way, a PRS that considers genome-wide SNPs can be defined 
as a weighted sum of allele counts for SNPs meeting a p-value threshold, 
yielding a set of PRSs for a vector of thresholds. In theory, this p-value based 
thresholding approach is also applicable to considering SNPs only within a 






Combining information for non-significant SNPs, but with lower-
ranked p-values, in addition to significant SNPs, the PRS analysis can be 
considered as a search to find an “optimal” p-value threshold corresponding 
to the SNP set R, which has the maximum possible predictive power 
compared to all other selected p-value thresholds. Thus in a parametric 
regression framework, the resulting PRS for each grid point or p-value 
threshold is regressed on the phenotype as target trait.  
Let us assume 𝑦𝑖
𝑡𝑎𝑟𝑔𝑒𝑡
 denotes a normally distributed phenotype of 
the target trait, the regression model is as follows: 
𝑦𝑖
𝑡𝑎𝑟𝑔𝑒𝑡
= 𝛽𝑃𝑅𝑆𝑃𝑅𝑆𝑖  + 𝜀𝑖        Eq 2.3  
where 𝛽𝑃𝑅𝑆 is the regression coefficient of PRS. The s number of distinct p-
value thresholds defined in the vector S, also determine the number of 
computed PRSs and thus the number of regression models in Eq. 2.3. The 
explained variance (R2) and association p-value of 𝑦𝑖
𝑡𝑎𝑟𝑔𝑒𝑡
 with the PRS is 
compared for those analysed models. The PRS among s the PRSs that 
explains the maximum variance in the phenotype, with significant evidence 
of association between yi
target
 and PRS of the model, is referred to as the 
optimal PRS (𝑃𝑅𝑆opt), and the corresponding p-value  threshold is called the 
optimal p-value  threshold (popt-value). Both steps, clumping and 
thresholding represent a statistical compromise between signal and noise 
[43]. Clumping aims to ensure the inclusion of truly predictive variants and 
reducing noise in the score by excluding variants that are highly correlated, 
while thresholding allows consideration of SNPs beyond the significance 
level [43, 45]. Thus using genome-wide SNPs, PRS analysis outputs a SNP 






2.3 Kernel Machine Regression  
Kernel methods are a machine learning class of algorithms that allow 
association testing of a SNP set with a phenotype of interest, reducing the 
dimensionality of tests greatly in comparison to the traditional GWAS [47]. 
Instead of single SNP analyses as in Eq. 2.1 we now consider a SNP set R 
with 𝑟 number of SNPs where  𝑔𝑖 denotes the vector of genotypes for the ith 
individual, such that 𝑔𝑖 = (𝑔𝑖1, 𝑔𝑖2, … , 𝑔𝑖𝑟)
𝑇 , 𝑖 = 1. , . . , 𝑛. Unlike the 
definition of SNP set R in the PRS analysis section, here the SNP set R can 
be the SNPs in the SNP set M, mapped to a gene or multiple genes 
belonging to a pathway.  
The regression model for the phenotype 𝑦𝑖  is as follows: 
𝑦𝑖 = 𝑥𝑖
𝑇𝛽 + ℎ(𝑔𝑖) + 𝜀𝑖      Eq. 2.4  
where ℎ(𝑔𝑖) is an unknown function, which models the genetic information 
for individual i in the model. 𝑥𝑖
𝑇 is the transposed vector of covariates that 
are parametrically modelled by the linear model. The genetic effects can be 
modelled via the function h with great flexibility, e.g., parametrically (such 
as via a PRS) or non-parametrically via a kernel function. Thus, in the kernel 
machine regression (KMR) model in Eq. 2.4, we test for association between 
a SNP set modelled via function ℎ(∙) and the phenotype, the hypothesis is 
as follows:  
𝐻0 ∶ ℎ(∙) = 0  𝑣𝑒𝑟𝑠𝑢𝑠    𝐻1 : ℎ(∙) ≠ 0         
2.3.1 Kernel function and association testing  
Let us assume the unknown function ℎ(𝑔𝑖) lies within a reproducing kernel 
Hilbert space ℋ𝐾 generated by a positive definite kernel function 𝑘(·,·). A 
reproducing kernel Hilbert space ℋ𝐾 allows the specification of a user-
defined feature map  𝜑 that in turn allows the transformation of data points 





The specific properties of the defined feature space 𝜑 do not require its 
explicit evaluation [49]. However, as per Mercer’s theorem, if a function 
𝑘(·,·) on the data points 𝑖 and 𝑗 satisfy Mercer’s constraints, then there exists 
a function 𝜑(·,·)  that maps 𝑖,  and 𝑗 into a higher dimension [50]. 
Mathematically, a kernel can be represented as follows:  
𝑘(𝑔𝑖, 𝑔𝑗) = <  𝜑(𝑔𝑖), 𝜑(𝑔𝑗) >      
Here 𝑘 denotes the kernel function, 𝑔𝑖 and 𝑔𝑗 are the r dimensional inputs 
from the genotype matrix G for any two individuals 𝑖 and 𝑗. 𝜑 is a map from 
𝑛 × 𝑟 −dimensional space to 𝑛 × 𝑛 −dimensional space. Thus, the 𝑛 ×
𝑟 −dimensional matrix G is converted into a 𝑛 × 𝑛 −dimensional kernel 
matrix 𝐾 , which is a symmetric and semi-definite positive matrix. Any 
element of the resulting 𝑛 × 𝑛 −dimensional matrix quantifies the similarity 
between any two individuals 𝑖 𝑎𝑛𝑑 𝑗 determined by the specified kernel 
function  𝑘(𝑔𝑖, 𝑔𝑗) . Thus, 𝐾 is also called the genomic similarity matrix [50].  
For genetic data, a simple and popular choice of kernel function is 
the linear kernel:  𝑘(𝑔𝑖, 𝑔𝑗) = 𝑔𝑖
𝑇 𝑔𝑗, which is a dot product between any two 
data points [47]. This indicates that the overall genetic effect is a linear 
combination of the individual effects in the SNP set R. Other kernels include 
the polynomial kernel 𝑘(𝑔𝑖, 𝑔𝑗) =  (𝑔𝑖
𝑇 𝑔𝑗 + 𝑐)
𝑑
 where c is a constant term 
and d is the polynomial degree, and the Gaussian kernel  𝑘(𝑔𝑖, 𝑔𝑗) =
 𝑒𝑥𝑝 (
−‖𝑔𝑖  − 𝑔𝑗‖
2
𝜌
⁄ ) [47]. To quantify similarity or dissimilarity between 
any two data points, numerous distance-based methods are available, such 
as Euclidian distance, Manhattan distance, Cosine similarity, Minkowski 
similarity, and Jackard Index [51]. For genetic data, methods such as 
identity–by-state, identity-by-descent, or shared-haplotype-based 





as well as genomic similarity measures, and relationships between them 
can be found elsewhere [25, 26, 52, 54]. 
In the KMR framework, once the kernel function is specified, the next 
step is to test the hypothesis. In Eq. 2.5, 𝐻0 ∶ ℎ(𝑔𝑖) = 0,  is equivalent 
to 𝐻0 : 𝜎Κ 
2 = 0,  where 𝜎Κ 
2  is the variance explained by the kernel function. 
Thus, a high-dimensional test is reduced to testing a single variance 
component. The regression model presented in Eq. 2.4 can also be viewed 
as a linear mixed model (LMM), assuming fixed effects for the design 
matrix 𝑋, a nonparametric function ℎ(𝐺) modelling the genetic information 
as random effect with ℎ(∙) ~ N(0, 𝜏2𝛫),  and 𝜀~𝒩(0, 𝜎𝜀
2𝛪) [52, 50, 47]. τ2 is 
the unknown variance component, which is expressed as a function of the 
scaling parameter 𝜆 and the variance σK
2   as follows: τ2 = λ−1σK
2  [47]. The 
overall variance 𝜎2 can be defined as 𝜎2 = 𝜎𝐾
2   + 𝜎𝜀
2 , and 𝜎𝜀
2 is the residual 
variance. The conditional distribution of  𝑦 given the random effects ℎ is 
normal:  𝑦|ℎ ~𝒩(𝑋𝛽 + ℎ,  𝜎2𝛪) and marginally (averaged across the 
individuals) 𝑦 ~ 𝒩(𝑋𝛽 ,  𝜏2𝛫 + 𝜎2𝛪) [49, 52, 54]. We can estimate ℎ by 
noticing the fact that the distribution of 𝑦 and ℎ is jointly normal and their 
covariance is  𝜏2𝛫 [52, 50, 47]. Making use of the conditional multivariate 
normal distribution, the expectation of ℎ given the observation 𝑦 can be 
estimated as  𝜏2𝛫 ∑−1(𝑦 − 𝑋𝛽 ̂) [49, 52, 54]. The estimates 𝛽 ̂ and ℎ are 
obtained by minimizing the penalized likelihood function for the KMR, 
which are equivalent to the best linear unbiased estimator and the best 
linear unbiased predictor of the LMM [47]. This connection bridges 
machine learning and regression statistics, specifically LMM and KMR, and 
allows for a unified framework of model fitting and statistical inferences 
[47]. We can estimate the variance component parameters  𝜏2 and 𝜎2 and 
any unknown parameter in the kernel function by maximizing the 
likelihood of the LMM. Thus, within the KMR framework, we test the 
following hypotheses, which intuitively are all the same:  𝐻0 ∶ ℎ(𝐺𝑖) =
0  𝑜𝑟  𝐻0 : 𝜎Κ 





The score test statistic can be derived by taking the first derivative of 
the restricted maximum likelihood (REML) equation with respect to 𝜎Κ 
2  and 
evaluating it under the null hypothesis [47].  The score statistic 𝑄 follows a 
mixture of chi-squared distributions under 𝐻0 and takes on the following 




2  (𝑦 −  ?̂?)
𝑇𝛫(𝑦 −  ?̂?)         Eq. 2.5 
 
where ?̂? is the fitted value of 𝑦 under the null model, and is easy to fit with 
standard regression models for fixed effects (e.g. linear regression for 
quantitative traits, or logistic regression for binary traits). The test statistic 
𝑄 depends on the true covariance matrix 𝛴 of  𝑦𝑖 , which is often unknown 
in practice and requires estimation of a large number of parameters. 
Although the sample covariance can be used to estimate 𝛴, it is not stable 
when the number of SNPs in the SNP set R is large or moderate and the 
number of individuals 𝑛 is small. Some statisticians use 𝜎𝜀 
2 in the 
denominator to compute the test statistics; others ignore this term and a 
formal derivation based on derivatives of the log-likelihood function would 
use 𝜎𝜀 
4 in the denominator. However, these variations are just different 
scalings of the quadratic form. As long as the scaling is considered, i.e. 
assuring that Q follows a mixture of chi-squared distributions, the resulting 
p-value will be valid [26, 49, 54]. The Satterthwaite approximation - an anti-
conservative approach and the Davies method- an analytical solution, have 
been used to compute p-values in the KMR. Between both computation 
methods for the p-value, the Davies method is more accurate. However, 
owing to computational constraints, the Satterthwaite approximation can 










3.1 PRS Approach in Correlated Phenotypes with Moderate to 
Small Sample Sizes 
My first article is a simulation study aimed at investigating the performance 
of polygenic risk scores (PRSs) in correlated phenotypes with varying 
sample sizes, typical in the clinical setting; with an application to real data 
[53]. The aims and questions of this study were motivated by our 
collaboration with the researchers from the PsyCourse study. As stated 
above, PsyCourse is a multicentre, transdiagnostic longitudinal study of the 
affective‐to‐psychotic continuum that combines longitudinal deep 
phenotyping and dimensional assessment of psychopathology [54].  
It is known that affective and psychotic disorders partially share 
psychopathological features and are genetically correlated [55]. Affective 
disorders, also called mood disorders, are mainly characterised by mood 
episodes and most typically involve bipolar disorders (Bipolar I and II), 
major depressive disorder, and mania [56]. Psychotic disorders, also 
referred to as delusion disorders, are mainly characterised by severe mental 
disorder that causes abnormal thinking and perceptions such as 
schizophrenia and schizoaffective disorder [56].   
At the time I employed the data from the PsyCourse study [54], the 
sample size was n= 771 individuals. Key questions addressed in this 





I. How much variance in the target traits of various sample sizes i.e., 
n=200, 500, and 1000 can be explained by the PRS, if both discovery 
and target trait are identical? 
II. In another situation in which the target and discovery trait are not 
the same but are correlated, how much variance can the PRS still 
explain in the target trait? 
III. How much prediction capability of the PRS is lost for target traits of 
multiple sample sizes that have a strong to weak degree of 
correlation with the discovery trait? 
IV. Can the results of the simulation analysis performed to address the 
questions stated in I, II, and III be interpreted with the real data 
application from the PsyCourse study? If Yes, then how? 
 
Before stating the findings of the simulation study, I would first like to 
introduce the simulation setup briefly. Keeping in consideration the sample 
size used in the GWAS summary statistics available for schizophrenia from 
the Psychiatric Genomic Consortium(PGC) [44], I simulated datasets for a 
quantitatively distributed discovery phenotype for N=34,000 individuals. 
Effect sizes for the causal markers were derived from the total heritability 
assumed for the discovery trait, i.e., 80%. I then performed a GWAS 
analysis to generate the summary statistics for the discovery sample. 
Furthermore, I generated datasets for four target traits, namely T1, T2, T3, 
and T4. The phenotype generation model for T1 was identical to that of the 
discovery trait. The target traits T2 to T4 were generated keeping a 
correlation r2 =0.8, 0.6, and 0.4 with T1. For all target traits, we generated 
datasets with varying sample sizes, namely n=200, 500, and 1000. The 
number of replicates for the simulation analysis described above was set to 
100.  
Given an identical discovery and target trait scenario as stated in 
question I, i.e. 100% common genetic aetiology, the variance (R2) explained 
by PRS substantially reduced from that of the total simulated trait 





sample sizes for T1. On average, the PRS based on summary statistics of the 
discovery trait explained 40% of the true simulated heritability. With the 
correlation structure between T1 and other target traits (T2-T4), the 
simulation results demonstrated an interesting agreement with a formula 
for loss in average explained variance by the PRS for sample size n=1000. 
On average, the loss in R2 decreased by the square of the correlation 
between T1 and other target traits. Thus, from T1 (average R2 = 0.32), the 
average R2 estimates decrease for T2 to R2 = 0.82 × 0.32 = 0.21, for T3 to R2 
= 0.62 × 0.32 = 0.12, and for T4 to R2 = 0.42 × 0.32 = 0.05. This gradual 
decrease in the average R2 estimates by the PRS from T1 to T4 corresponds 
well with decreasing empirical correlation among target traits. With the 
decreasing sample size for T2-T4, the loss in R2 by PRS became more 
evident. Moreover, the difference in the smallest and largest values of R2 
across the 100 simulation replicates increased with decreasing sample size, 
indicating a higher probability of finding false positive results.  
I compare these findings of my simulation analysis with results of a 
dataset from the PsyCourse study. Briefly, after removing missing data 
from our considered phenotypes for the analysis, our sample size reduced 
to n=653 individuals. The individuals in the PsyCourse study belonged to 
two diagnostic groups: affective (n= 266) and psychotic (n=386). Thus, I 
analysed the total dataset and each diagnostic group separately. In the 
analysis, I used two well-developed psychosocial functioning scores, 
namely the Global Assessment Function (GAF) score and the Positive and 
Negative Syndrome Scale (PANSS) score from the PsyCourse dataset as 
target phenotypes. I used the GWAS summary statistics for schizophrenia 
(SZ; as discovery trait) available from the Psychiatric Genomic consortium. 
Only a small amount of variance was explained by the SZ-based PRS for 







3.2 Kernel Machine Regression for DNA Methylation Data 
(CpG) and Modelling the Interaction Term between SNPs 
and CpG Variants 
In the second article, I investigated a very well-known set-based semi-
parametric regression approach called kernel machine regression (KMR) 
now for DNA methylation (DNAm) data [57]. Previous research done by 
our group [58, 59] investigated the existing kernels and developed new 
kernels for genetic data association testing with the KMR approach. In the 
methods section, I have briefly highlighted how KMR works for genetic 
datasets. However, unlike the SNP or genotype data that are encoded as the 
count of minor alleles in a SNP (i.e. 0, 1, or 2 respectively), the DNAm data 
for CpG markers vary continuously between 0 and 1, depicting the 
methylation state of the respective marker. An individual CpG marker is 
assumed to have beta distribution, with two parameters α and β controlling 
the shape of distribution. Thus, data from methylation are not necessarily 
normal.  
The research work towards the second article is my contribution to 
Genetic Analysis Workshop 20 (GAW20). GAW20 provided genome-wide 
genotype (bi-allelic SNPs) and DNA methylation levels (CpG) from the 
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study [60]. 
GOLDN is a longitudinal (four data points: visits 1 to 4) family-based study 
involving 991 participants of European descent. The study goal was to 
localize novel loci contributing to triglyceride (TG) and very-low-density 
lipoprotein cholesterol (VLDL-C) response in connection with a lipid-
lowering drug. Blood levels of TG and VLDL-C were measured before the 
diet (visits 1 and 2) and after drug intervention (visits 3 and 4). DNAm 
levels of CpGs were collected only at two time points, during visits 2 and 4. 
Visit 1 and 2 were one day apart from each other, as was the case for visits 
3 and 4. However, visit 2 and 4 were three weeks apart from each other. The 
data obtained on DNA methylation during visit 2 and 4 were generated 





CpGs markers, namely cg00574958, cg17058475, cg01082498, and 
cg09737197 in intron 1 of the carnitine palmitoyltransferase 1A (CPT1A) 
gene with strong evidence of association with VLDL-C and TG (Irvin et al., 
2014). 
 In addition to the real datasets from GOLDN study, GAW20 also 
provided simulated datasets generated with a model using the GOLDN 
study real sample, genotype, and methylation datasets. The answer sheet 
provided by GAW20 described the simulation model. Post-treatment 
methylation levels were modelled based on pre-methylation with a higher 
variation at ten CpG markers than for the remaining CpG markers. Post-
TG levels were influenced by five causal SNPs with decreasing heritability 
and several polygenes. However, the influence of each of the five causal 
SNPs on the TG levels (pre to post) decreased with increasing degree of 
methylation of nearby CpG markers to the causal SNPs, such that five out 
of ten CpG markers were close to the causal SNPs. Using the information 
from the findings of the GOLDN study and the answer sheet for the 
simulated data from GAW20, I defined genomic regions harbouring causal 
and non-causal SNPs and their nearby causal and non-causal CpGs.  
I investigated both simulated and real datasets and our research aimed 
to address the following questions:  
I. Can KMR be implemented for the sets of CpG markers that do not 
follow a normal distribution?  
II. How does the kernel work, by increasing the size of genomic region 
under analysis or by incorporating more CpGs into the kernel? 
III. Does a model that considers an interaction term between the pair(s) 
of nearby SNP and CpG markers improve the overall performance 
of the model? This corresponds to a genetic by epigenetic interaction 
term (genome-by-epigenome interactions)? 
I restricted my analysis only to independent individuals in both 





to n=150 individuals in the real dataset and n=111 individuals in the 
simulated datasets. Thus, a loss of power in the analysis was expected. A 
research focus of our group was on kernel methods for genetic datasets, so 
that SNP-sets were jointly tested for association. I also adapted the set-
based approach for CpG markers. Here, two crucial aspects concerning 
CpG markers need attention: first, the 450K methylation array only gives 
information for CpGs that are located either inside or close to protein-
coding genes. Secondly, the CpG density in the human genome is not 
uniform. Research has revealed that instead of a single CpG site/variant, 
few to several CpGs as a CpG-set within a genomic region exhibit a similar 
pattern of methylation [29, 61]. This CpG-set controls the transcriptional 
activity of nearby genes. Considering the non-uniform density and the set-
based behaviour of CpGs, I defined genomic regions of interest of varying 
length. In the simulated data, the genomic regions were defined within the 
boundaries of lying zero kilobase pairs (kbp), 3 kbp, and 15 kbp upstream 
and downstream of true causal markers. In the real data, the boundaries of 
genomic regions were defined using the intronic boundaries of CPT1A, as 
reported evidence by the GOLDN study findings for association of CpG 
markers with the TG levels are mapped to CPT1A.  
Overall, the analyses for both the real and simulated data indicated that 
the use of KMR for CpG markers is feasible. I modelled the set of CpGs in 
defined genomic regions via a linear kernel in the KMR. In addition, a linear 
model was used to validate the findings by the linear-kernel-based KMR. 
In particular, even though I only considered independent individuals for 
analyses, KMR was able to replicate the association from the original study, 
albeit nominally. For simulated data, no direct effect of CpG markers was 
modelled; the KMR approach did not yield any significant findings. My 
results for KMR were supported with that of linear regression analysis. 
Most importantly, an interaction regression model for the causal SNP with 
the nearest CpG marker identified an effect for the SNPs with the three 





effect only for unmethylated regions, decreasing to zero in the case of full 
methylation. Thus, in the context of a clear candidate setting, interaction 
between epigenetic and genetic data may enhance information, albeit 










Many parametric and non-parametric methods have been developed and 
tested for the set-based association testing of genetic datasets with complex 
phenotypes. In this thesis, I present two set-based approaches, polygenic 
risk scores (PRSs) for genetic data and kernels for genetic and methylation 
data. PRS is an often-applied strategy that calculates a genetic risk score for 
a particular phenotype based on GWAS summary statistics obtained from 
an independent sample.  
In my first research article [53], I investigated the use of GWAS 
results for target traits that are not identical to the discovery trait but might 
have a strong-to-moderate correlation. Our collaboration with psychiatrists 
based in Munich working on the Psycourse study [54], motivated this 
research. Sergi Papiol and his workgroup conducted a longitudinal study 
in 2019 recruiting schizophrenia patients and healthy controls, in which all 
study participants went through aerobic endurance training for three 
months [62].  Magnetic resonance imaging (MRI) scans were collected at 
baseline and at the end of training. PRSs were calculated using the GWAS 
summary statistics of schizophrenia available at the PGC [44]. A change in 
hippocampal volume before and after training was found to be associated 
with the schizophrenia PRS. Change in hippocampal volume is a 
psychopathological endophenotype [63]; when used as a target trait, it 
reflects a situation of modest to strong correlation between the target and 
discovery traits. In the PsyCourse study, several other psychopathological 
endophenotypes such as cognitive functions investigating the working 





In molecular psychiatric research, endophenotypes have gained 
quite a lot in momentum in the last few years [54]. It is speculated that 
endophenotypes share genetic burden in the affective-to-psychotic 
continuum of psychiatric disorders, and they tend to appear in both 
patients and their unaffected relatives [64]. Hence, endophenotypes can 
potentially decipher the genetic burden of disease better than the 
transdiagnostic groups. Significant associations have been reported for 
schizophrenia-based PRS analysis with P300 and the digit-span test, two 
commonly recorded psychopathological endophenotypes [65].  
My simulation study provides an insight into using various 
endophenotypes where the magnitude of genetic correlation between an 
endophenotype and the discovery trait is different. The relevant GWAS 
summary statistics can be used while taking into account the sample size of 
the target trait under PRS analysis. The findings of my study can also be 
used for situations of correlated diseases, such as taking T2DM as an 
endophenotype/risk factor in cardiovascular disease. 
Although the applications of PRS have been useful for various 
complex diseases, this method has many limitations. First, PRS requires 
appropriate and relevant GWAS summary statistics calculated on a very 
large sample [43]. Such large-scale GWAS results are only available for a 
few complex diseases. Moreover, a wide majority of these GWASs are 
performed on individuals with European ancestry [46]. Therefore, PRS is 
calculated for the target sample with the same genetic ancestry.  
In the PRS studies conducted between 2008 and 2017, 67% of these 
studies included participants exclusively with European ancestry, 19% 
included participants with East Asian ancestry and only 3.8 % of studies 
were performed for African, Hispanic, or other indigenous ancestry [46]. 
Duncan et al., 2019 performed an interesting PRS analysis with admixture 
populations using height as discovery and target trait. In the above state of 





individuals, were used from the UK Biobank. However, for the target trait, 
individuals with African ethnic ancestry were employed. A linear 
regression model as function of age, gender, as well as European ancestry 
components with and without PRS revealed that the predictive 
performance of European ancestry-derived polygenic scores is lower in 
non-European ancestry samples [46]. Thus, the underrepresentation of non-
European GWASs limits the predictive power of PRSs.  
More recently, Middle East Asian countries [66, 67] have taken the 
initiative and established data banks similar to the UK Biobank such as the 
Saudi Human Genome Project and Qatar Biobank for medical research. 
Biobanks in East Asian countries such as China (Pan-Asia Population SNP 
Database; Human Genetic Resources Platform), South Korea (Korean 
Genomic Variant Database; Korea Biobank Project), Japan (Japanese 
Genotype-Phenotype Archive; Biobank Japan), and Taiwan (Taiwan 
Biobank) were established earlier. In the South East Asian countries such as 
Pakistan and India, no biobanks have been established yet; however, 
numerous GWASs targeting phenotypes such as T2DM and lung cancer 
have been carried out there. In PRS analysis, the model is adjusted for 
population stratification; principal component analysis (PCA) and 
multidimensional scaling (MDS) are frequently used. However, there is 
need for development of methods that allow combining data from admixed 
populations. In addition, there is the need to conduct well-powered studies 
in non-white populations. 
PRS facilitates the evaluation of relative risk in individuals. Hence, it 
cannot be used to infer the absolute risk of genetic predisposition for a 
particular disease in a particular individual. Numerous PRS analyses have 
demonstrated that adding known non-genetic risk factors along with the 
PRS in the regression model has resulted in an increase in the explained 
variance of the target trait, thus improving the risk stratification in 
individuals in the target sample. The performance of risk models can be 





area under the curve (AUC) [68]. The clinical utility of models with an AUC 
< 0.65 is generally not very great. Models with an AUC > 0.8 are generally 
informative for most patients, and can be used for clearer stratification of 
study participants into groups of high, intermediate, and low risk.  
In the second article, I implemented a kernel method, which allows 
joint testing of a set of markers with a phenoytpe. Kernel methods have 
been well exploited for genetic datasets based on SNPs. Previous research 
work done by our group has demonstrated the use of kernels for dependent 
and independent individuals in a dataset, as well as developing a kernel 
that allows the incorporation of pathways with interacting genes. For my 
research work, I used the linear kernel for methylation datasets (set of CpG 
markers). CpG markers have often been employed as response variable and 
associated with gene expression datasets. In my work, I considered a 
reverse regression model that associates the phenotype with the CpG 
markers. For the regression model in which CpG markers are employed as 
response variable, a logit transformation is applied to normalise the CpG 
values, as these are beta-distributed. However, a CpG value that is 
continuous from 0 to 1 yields infinity and zero for 0s and 1s in the data after 
logit transformation. In order to overcome this problem, the original data 
interval of values is reduced such that 0s and 1s are replaced. This results 
in a severe loss of information. The untransformed value is referred to as B-
value. After logit transformation, these are called M-values. In my second 
article, I used B-values with a limited sample size of n<200 individuals in a 
linear kernel. 
Subsequently, I performed simulations (results not published) to 
compare the performance of the linear kernel by using B-values versus M-
values. Using a copula-based approach through beta distribution, I 
generated methylation datasets for a quantitative phenotype y. I considered 
various scenarios based on correlation structure, i.e., from no correlation to 





In all these scenarios, I found that using the logit transformed M-values 
resulted in a loss of power, albeit not significant. 
Furthermore (results not published), I considered using an additive 
kernel that combined genotype and methylation datasets in one kernel, and 
testing the association with the outcome y. The simulation scenarios were 
the same as stated above, with varying numbers of SNPs and CpGs in each 
dataset. First, simulation results testing the association with the outcome 
revealed that the power remained approximately the same for an additive 
kernel for a SNP set, regardless of whether or not the CpG set was added 
into the kernel. These results are in good agreement with Zhao et al., 2018 
[69]. In these simulations however, I simulated CpG markers that were a 
mixture from the three distributional shapes for methylation, i.e. 
hypo/semi/hyper-methylated, and this, along with the SNP set, did not 
really improve power. Thus, I subsequently simulated CpG markers only 
from one distributional pattern; the performance of the additive kernel 
varied then. More simulations are required to test the power of an additive 
kernel integrating a methylation-state-specific CpG set with a SNP set into 
one kernel.  
The research work completed in preparation of this thesis 
contributes to the use of the PRS technique for correlated target traits with 
careful consideration of the sample size, in particular for clinical studies. In 
addition, the research into implementing kernels for methylation datasets 
hints towards exploiting the opportunity of investigating other -omics 
datasets by deploying other kernels. Given the existing understanding of 
the genetic architecture of complex diseases, an additive model of 
heritability is used.  The importance of interactions is unclear and the 
additive model seems to capture more variance than the interactions when 
simple models for the interaction are employed. Kernel methods seem a 
promising strategy for multi-omics data integration. Moreover, the 





knowledge such as that available on the ENCODE database or the Gene 
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Abstract
In GAW20, we investigated the association of specific genetic regions of interest (ROIs) with log-transformed
triglyceride (TG) levels following lipid-lowering medication using epigenetic and genetic markers. The goal was to
incorporate kernels for cytosine-phosphate-guanine (CpG) markers and compare the kernels to a purely parametric
model. Post-treatment TG levels were investigated for post-methylation data at CpG sites and region-specific SNPs
and adjusted for pre-treatment TG levels and age, in independent individuals only (real data: n = 150; simulated
data, replicate 84: n = 111). In both data sets, our single-CpG-marker results using kernels and linear regression were
in good agreement. In the real data, we investigated the introns of the CPT1A gene previously reported as
associated with TG levels as separate ROIs, and were able to find hints of an association of cg17058475 and
cg00574958 with post-treatment TG levels. In the simulated data, we investigated a total of 10 regions, in which
the 5 causal and 5 non-causal markers lie, respectively, with increased methylation variances, yielding plausible
results for the 3 window sizes. Overall, this indicates that kernels for CpG markers are feasible. An interaction
regression model for the causal SNP with the nearest CpG marker identified an effect for the SNPs with the three
greatest heritabilities simulated. The simulation model assumed full SNP effect only for unmethylated regions
decreasing to zero in the case of full methylation. Thus, in the context of a clear candidate setting, interaction
between epigenetic and genetic data may enhance information, albeit nominally, even with small sample sizes.
Relieving the burden of multiple testing, developing kernels further to analyze data from multiple omics jointly is
well warranted.
Background
The human genome is a highly intricate system compris-
ing various genic and gene regulatory elements. Epigen-
etic intervention turns it into a jungle. High-throughput
technologies have been used to profile phenotypes in
multiple omics dimensions. In order to dissect complex
genomic traits, statistical tools need to handle a multitude
of markers both within and across such dimensions. The
kernel score test (KST) enables us to test a set of markers
for an overall association with a phenotype [1], such as
those markers within a region of interest (ROI). It highly
reduces the burden of multiple testing without simply
aggregating the data. KST can be applied to common and
rare variants, or adjusted for covariates and applied
to data of genome-wide association studies (GWAS),
epigenome-wide association studies, or sequence data
(where it was named the sequence kernel association
test [2]).
Our previous research [3, 4] focused on genetic data and
mainly on logistic regression. In the current analysis, we
focused on the use of the KST, employing methylation
markers to investigate a normally distributed drug re-
sponse in independent participants. In several regressions
we modeled post treatment log-transformed triglyceride
(post-lnTG) as a function of epigenetic and/or genetic
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markers or kernels thereof, adjusting for pre-treatment
log-transformed triglyceride (pre-lnTG) and age. We ini-
tially investigated the use of KST for epigenetic markers
alone and then with genetic markers. We analyzed




The GAW20 data were provided by the Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN)
study [5], a longitudinal family-based study involving
991 participants of European descent to localize novel
loci contributing to triglyceride (TG) response in con-
nection with fat loading and fenofibrate treatment. Data
were collected at 4 time points: visits 1, 2, 3, and 4. We
performed a pre−/post-treatment analysis using only
visits 2 and 4, as the time between visits 1, 2 and 3, 4
was only one 1 day and the pre- and post-methylation
data were only recorded at visits 2 and 4. To normalize
distributions, TGs were log-transformed (pre-lnTG and
post-lnTG). In addition, we used post-methylation data,
GWAS data, and age.
GAW20 also provided simulated data using a family
structure and genotypes identical to those in the original
data. The answer sheet we were provided described the
simulation model. Post-treatment methylation levels
were modeled based on pre-methylation with a higher
variation at ten 10 CpG cytosine-phosphate-guanine
(CpG) markers than for all others. TGs were influenced
by five 5 causal SNPs with decreasing heritability and
several polygenes. However, the influence of each of the 5
causal SNPs on log TG change decreased with increasing
degree of methylation in that particular ROI. Five of the
10 CpG markers were those close to the causal SNPs. We
defined the corresponding region as causal ROI and the
other mentioned regions as non-causal ROIs.
Since we were focusing only on independent individ-
uals with available phenotypic and genetic/epigenetic
information, we only included exactly one member from
each pedigree. Hence, we included 150 individuals from
the real data and 111 individuals from the simulated
data of replicate 84.
Selection of ROIs
We first investigated models with and without kernels
with post-treatment methylation data. To define ROIs
for the simulated data, we consulted the GAW20 an-
swers for the 5 causal and 5 noncausal CpG markers
and associated SNPs to define 10 ROIs with the bound-
aries lying 0 kilobase pairs (kbp), 15 kbp, and 3 kbp
upstream and downstream of each of these 5 + 5 CpG
markers. In the real data, we formulated sets of CpG
markers in the CPT1A gene defined by intronic boundaries.
All the genomic information is in build hg18. After this we
began to investigate genetic markers and used the know-
ledge of the model for effect simulation.
Regression models and KST
To investigate the association of specific ROIs with
post-lnTGs, we employed linear and semi-parametric
kernel regressions, all adjusted for age and pre-lnTG.
In the KST, we used a linear kernel to transform the
available epigenetic (or genetic) information of the n
individuals into a similarity matrix K. This is calcu-
lated as K = ZZt, where Z is a n ×mu matrix for n in-
dividuals and mu markers of region u. It models a
linear effect of the considered markers on the re-
sponse Y. Let Y = (Y1,…,Yn) denote the post-lnTGs. Y
is modeled as:
Y ¼ XbT þ h Zð Þ þ ε ð1Þ
where X is the matrix for known fixed covariates, includ-
ing age and pre-lnTG; b is the vector of corresponding
regression parameters; and ε denotes the usual residuals.
The non-parametric function h(Z) depends on the n × n
dimensional kernel matrix K (for more details refer to
Schaid [1]). The KST investigates whether the epigenetic
(or genetic) covariance component h(Z) equals zero or
not. It is computed from maximum likelihood estimates
for the parameters of the null model. The p values were
calculated using Davies’ exact method [6] with the R
package CompQuadForm [7].
To investigate CpG markers only, we employed a
linear regression that included the marker itself, as well
as a kernel regression including a kernel for the ROI.
For this kernel, we used three different windows, all of
which included the CpG marker itself and windows of
Table 1 Simulated data: association of 10 candidate CpG markers
and their ROIs with post-lnTG adjusted for pre-lnTG and age
ROI CpG ID KST, Window Size Regression
±15 kbp ±3 kbp ±0 kbp
ROI-1 cg00000363 0.86 0.15 0.37 0.49
ROI-2 cg10480950 0.09 0.09 0.58 0.63
ROI-3 cg18772399 0.65 0.65 0.56 0.57
ROI-4 cg00045910 0.61 0.71 0.73 0.89
ROI-5 cg01242676 0.49 0.33 0.49 0.57
ROI-6 cg00703276 0.13 0.13 0.53 0.62
ROI-7 cg01971676 0.51 0.51 0.97 0.98
ROI-8 cg11736230 0.79 0.83 0.22 0.18
ROI-9 cg12598270 0.15 0.15 0.69 0.81
ROI-10 cg00001261 0.78 0.79 0.58 0.61
p Values were computed by KST with varying window sizes including the CpG
marker or by single-marker linear regression
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sizes ±0 kbp, ±15 kbp, and ± 3 kbp. After investigating
CpG markers only, we applied a linear regression includ-
ing the causal SNP marker x1 with its corresponding/
nearest CpG marker x2 and their interaction for the 5
causal SNP markers:
Y ¼ β0 þ β1x1 þ β2x2 þ β12 x1  x2ð Þ þ covariates þ ε
ð2Þ
p Values are not adjusted for multiple testing. The




We performed region-based KST and linear regression
to analyze the association of the post-treatment methyla-
tion in the 10 candidate ROIs with post-lnTG adjusted
for pre-lnTG and age. Table 1 lists the p values for the
kernel with the candidate CpG marker and windows of
sizes ±15 kbp, ±3 kbp, and ± 0 kbp, and for single-marker
regression analysis. Other than ROI-1, the results for the
KST with several CpG markers (±15 kbp, ±3 kbp) are
comparable. Furthermore, the results for a single CpG
marker (KST ± 0 kbp, simple regression) are also similar.
As to be expected from the simulation, no significant
associations were found.
Subsequently, we performed the KST that incorpo-
rated genetic information by employing the causal SNPs
nearest to the CpG markers considered above. As
expected, this did not yield significant associations (data
not shown). Lastly, for the 5 causal ROIs, we employed
the regression model defined by eq. (2) with causal SNP,
nearest CpG marker, and their interaction. Table 2
presents the results. We found nominally significant as-
sociations for the first three SNPs in ROI-1, ROI-2, and
ROI-3. The SNPs rs9661059, rs736004, and rs1012116
had the greatest heritabilities of the 5 causal SNPs (see
GAW20 answers). These effects could only be detected
by including the nearest CpG marker. Three significant
main effects (for rs9661059, rs736004, and rs1012116)
and two significant interaction effects were found
(Table 2). Our results are in good coherence with the
simulation setup of GAW20, in which the effect of the
causal SNP is at a maximum in an unmethylated region
and decreases as the degree of methylation in the region
increases.
Real data
We analyzed the introns of the CPT1A gene. Table 3 pre-
sents all the results. Intron 1 includes the CpG markers
previously reported as associated with (baseline) TG [5].
Thus, we investigated single CpG markers of that intron
and found two hints for associations with post-lnTG for
cg17058475 and cg00574958 (Table 4). Again, the KST and
single marker linear regression are in good agreement.
Discussion
In this analysis, the small sample size that results from
using only independent individuals limits our power.
Nevertheless, we were still able to detect nominally sig-
nificant associations for 3 of the 5 causal SNPs from the
simulation employing a model of interaction with their
nearest CpG marker. We also found hints for association
of cg17058475 and cg00574958 in intron 1 of the
CPT1A gene with TGs in the real data by employing
KST and the linear regression model. The GOLDN study
also reports cg17058475 and cg00574958 are also re-
ported by GOLDN study to be as associated with TGs
and cg00574958 as correlated with CPT1A expression
[5]. Working on the simulated data, we investigated
CpG markers in 10 ROIs. A region several kbp in size
contains far fewer CpG markers than SNP markers. We
revealed for the KST that the window size 0 kbp is
similar to linear regression and higher window sizes are
similar to each other, yet different from 0 kbp. As no dir-
ect CpG effect was modeled, no additional conclusions
can be drawn. However, the application of the kernel
proves feasible with CpG markers, and not only with
genetic markers [3, 4]. Here the use of the kernel is not
crucial, as the effect was only given by a simulation
model for the causal SNP and the nearest CpG marker,
not involving other markers in the region.
The most common design for a treatment-response
study is a cohort design with independent people that re-
quires individuals to take the treatment. This might often
be unethical for families as a whole (albeit reasonable in
Table 2 Simulation data: association of 5 causal SNPs and their
nearest CpG marker with post-lnTG, adjusted for pre-lnTG and age
ROI CpG ID SNP ID CpG Marker SNP CpG × SNP
ROI-1 cg00000363 rs9661059 0.0846 0.0187 0.0484
ROI-2 cg10480950 rs736004 0.0192 0.0237 0.0192
ROI-3 cg18772399 rs1012116 0.1447 0.0367 0.1933
ROI-4 cg00045910 rs10828412 0.9252 0.4915 0.9708
ROI-5 cg01242676 rs4399565 0.0649 0.3519 0.0756
p Values of interaction model Eq. 2
Table 3 Real data: association of sets of CpG markers in 14 introns of the CTP1A gene with post-lnTG, adjusted for pre-lnTG and age
Intron number(Int) Int1 Int3 int 4 Int5 Int 6 Int7 Int 9 Int10 Int12 Int13 Int14
p Value 0.08 0.74 0.03 0.76 0.95 0.46 0.12 0.09 0.01 0.46 0.59
p Values computed by KST
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the GOLDN study). As we wanted to see the behavior of
kernels and regression in this general context, we opted to
focus on unrelated individuals. Our strategy can be
adapted for family data. In GAW19, we used KST on
family data by introducing a design matrix—ZcT in
Eq. (1)—where random effects c caused by familial
polygenic background are adjusted for Y and Y =
XbT + ZcT h(Z) + ε (for more details, see Malzahn et al.
[3]). Several GAW20 contributions to this volume used
the theoretical or the estimated kinship matrix to con-
struct the random effect in a linear mixed model.
Conclusions
Our analysis with multi-omics data in a linear regression
interaction model in comparison to single omics data in
KST and linear regression framework emphasizes that
careful integration of multi-omics data might enable re-
searchers to explain a greater proportion of the variance
in complex traits, even in small samples. Consequently,
it would seem highly warranted to extend kernels to
incorporate multiple types of omics data.
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ABSTRACT 
In psychiatry, polygenic risk scores (PRSs) have recently been exploited 
to uncover the shared genetic components in distinct psychiatric 
disorders. Summary data of large-scale discovery genome-wide 
association studies (GWASs) on traits such as schizophrenia (SZ) are 
available. In addition, clinical deep phenotyping includes several 
correlated phenotypes for psychosocial functioning such as the Positive 
and Negative Syndrome Scale (PANSS) and the Global Assessment of 
Functioning (GAF). PANSS evaluates acute symptom severity, thus 
adjusting for this effect when measuring overall assessment and 
progression of patients with the GAF. A far-reaching understanding of 
the properties of PRS in such phenotypes is critical to interpreting such 
analyses, especially when the intermediate phenotype limits sample size.  
We conducted a simulation study to investigate the performance of PRS 
in the correlated target phenotypes using sample sizes n = 200, 500, and 
1000 (100 replicates) in terms of explained variance in the simulated 
target phenotypes. We investigated performance of SZ-PRS in the 
PsyCourse study involving 653 patients (psychotic n = 387, affective  
n = 266), in which SZ-PRS was derived from the results of a large GWAS of 
schizophrenia by the Psychiatric Genomics Consortium.  
Our simulation results reveal that decreasing correlation between target 
phenotypes indicates a definable decrease in shared genetic burden with 
the discovery phenotype. However, with a small sample size, there is 
already a loss in retrieved R2 with an identical generation model. Our 
PsyCourse results portrayed that for all patients and for psychotic 
subgroup, SZ-PRS explained 1% R2 for GAF. 
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INTRODUCTION 
Large-scale genome-wide association studies (GWAS) for a variety of 
polygenic phenotypes have greatly increased the amount of information 
available, e.g., by providing summary statistics including effect sizes and 
p-values for single nucleotide polymorphisms (SNPs) with respect to the 
association with those phenotypes. This has enabled researchers to 
develop numerous statistical methods such as the polygenic risk score 
(PRS) approach to exploit the pleiotropic and polygenic properties of 
complex traits. The PRS aggregates information from a large number of 
potentially causal SNPs that have fairly small effect sizes. It is commonly 
used to model and predict pleiotropic traits and also to identify 
individuals at risk. PRS may be defined as the sum of weighted counts of 
risk alleles, where the weights are recruited from the effect sizes of the 
corresponding large-scale GWAS results. 
PRS can be regarded as the underlying genetic liability for a 
phenotype, usually following a normal distribution [1]. Genetic liabilities 
of various complex phenotypes and disorders such as height [2–4] and 
schizophrenia [5–7] have been estimated by taking into account 
hundreds or thousands of genetic loci in this additive polygenic model. 
PRSs based on the GWAS results of one phenotype in a large-scale sample 
(discovery) can also be used to quantify the degree of variance explained 
by the PRS in another, possibly much smaller sample with the exact same 
or sufficiently correlated phenotype (target). The PRS for the phenotype 
schizophrenia (SZ), denoted as SZ-PRS, has been used for example to 
unveil the polygenetic model behind several psychiatric phenotypes such 
as first episode psychosis (FEP) [8–10] and bipolar disorder (BPD) [11]. 
Substantial evidence from well-powered GWAS revealed a 
considerable shared genetic etiology among distinct psychotic 
phenotypes such as SZ and BPD [11]. However, it is well known that 
psychotic disorders are highly heterogeneous in their symptoms and 
genetic architecture [8–10]. Owing to the presence of considerable 
overlap in the dimensions and severity of symptoms, numerous clinical 
scales have been developed that altogether allow us to assess the 
functioning of patients with various distinct psychiatric phenotypes. 
Among a number of standard testing scales and procedures in psychiatry, 
Global Assessment of Functioning (GAF) is one of the well-known 
standard rating scales for all psychiatric phenotypes. The GAF score 
varies from 1 to 100, higher scores reflecting an increase in mental 
health and capability of coping and vice versa [12]. The Positive and 
Negative Syndrome Scale (PANSS) is used to measure symptom severity 
in psychiatric patients, and is considered as a measure of acute 
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symptoms. It has three subscales that quantify positive, negative, and 
global psychopathology symptoms on 30 individual symptoms [13]. GAF 
is often adjusted by PANSS, so that it is less influenced by acute 
symptoms. The correlation among different symptom dimension scores 
such as GAF and PANSS varies with the specific clinical diagnosis [8,9]. 
Recently, SZ-PRS has been exploited to explain the shared polygenic basis 
of GAF and PANSS for distinct diagnostic groups in FEP patients with 
schizophrenia [8,9]. However, the prediction of these distinct genetic 
components in phenotypes with respect to symptoms remains a challenge 
and the degree of genetic correlation between psychiatric phenotypes and 
the severity of symptoms is yet not completely understood. 
In the current study, our first goal is to elucidate the performance of 
PRS in a simulation study of correlated quantitative phenotypes. Previous 
simulation studies estimated the performance of PRS across various 
heritabilities and shared genetic correlation scenarios assuming that all 
markers are independent [1,11]. Here we investigated the behavior of 
PRS by taking the linkage disequilibrium (LD) structure of the population 
into account. We examined the properties of PRS for correlated 
quantitative phenotypes with complete overlap of causal genetic markers 
with a focus on the distribution of explained variance (R2) and optimal  
p-value threshold (p0) in the replications. Our second goal was to 
interpret our simulation results in view of the SZ-PRS applied to 
phenotypes in the PsyCourse dataset (version 2.0.1) [14] including 653 
psychotic and affective individuals and to compare our findings with 
previous studies [8,9]. We analyzed the symptoms and severity in terms 
of the association between GAF and SZ-PRS. We then stratified the data 
by diagnosis, i.e., into psychotic and affective individuals, in order to 
examine whether potential effects of symptom severity in the GAF are 
restricted to diagnostic groups or are a more general phenomenon.  
MATERIALS AND METHODS 
Polygenic Risk Score Approach  
PRS exploits shared genetic etiology between a discovery and a target 
trait. The discovery and target trait may be the same where the shared 
genetic etiology is 100% or any two distinct phenotypes with a varying 
degree of shared genetic correlation between them. We investigated the 
performance of PRS applied to samples of varying sizes of the target trait 
in both a simulation study as well as on real-world psychosis data. We 
considered target traits that are correlated to the discovery trait at 
varying degrees of correlation. Typically, a PRS is constructed as a 
weighted sum of risk/protection allele counts (xi) with weights (βi).  
i ii
PRS xβ=  
The weights are obtained from the single SNP summary statistics 
estimates of a GWAS regression analysis and dosages instead of the risk 
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allele count may also be employed for imputed SNPs for the target 
sample. For a binary discovery trait such as SZ in the Psychiatric 
Genomics Consortium (PGC) study [5,6], the weights are given by the log 
odds ratios (log OR). For a continuous discovery trait, linear regression 
coefficients are used as weights whenever appropriate. 
In the PRS analyses, the first step is to perform a GWAS analysis on a 
discovery sample and subsequently rank SNPs on the basis of their  
p-values when testing the association with the discovery trait. Next, all 
the common SNPs were identified that have been genotyped or imputed 
in both the discovery and the target trait; and in the following we refer 
only to those common SNPs for calculating the PRS. For a given p-value 
threshold pt, the PRSt for an individual of the target sample is constructed 
as described above by including all SNPs with p-values for association 
with the discovery trait smaller than or equal to the given threshold. In 
the target sample, the target trait is then regressed on the PRSt, in 
separate regressions for a dense grid of p-value thresholds pt. For each 
regression, i.e., each threshold pt, the variance explained by PRSt, denoted 
by Rt2, is estimated. Finally, PRSt = PRS explaining the maximum amount 
of variance (Rt2max = R2) and its optimal p-value threshold (p0) are 
determined. In principle, all common SNPs between discovery and target 
trait or a subset could be used in a PRS analysis. The subset could be 
simply those SNPs demonstrating significant GWAS results, such as the 
108 loci identified in the PGC SZ GWAS [5]. However, unless indicated, we 
do not use such a restriction based on significance when calculating the 
PRS. In the global approach, it is recommended to use a subset of SNPs 
yielded by clumping the GWAS results before computing risk scores [15]. 
In theory, clumping refers to a variable selection procedure that 
preferentially retains SNPs with the strongest statistical evidence, i.e., 
lowest p-value, within each LD-block. Thus the number of SNPs and the 
correlation between the SNPs is greatly reduced in the construction of 
the PRS. The value of a PRS at any particular threshold is named the 
genetic burden with respect to the discovery trait, e.g., SZ genetic burden.  
PsyCourse Data 
We obtained imputed genotypes based on original genotyping with 
the Illumina Infinium PsychArray as well as the top ten principal 
components (PCs) of ancestry for n = 771 patients from the PsyCourse 
study [14]. We considered baseline information on symptom severity in 
these patients [14]. PsyCourse is an ongoing multicenter study in 
Germany and Austria that aims to understand the genetic-molecular 
underpinnings of the longitudinal course of the affective-to-psychotic 
continuum (for details see [14]). All patients in the study were classified 
into two broad diagnostic groups, psychotic and affective. Briefly, 
diagnoses of each patient were established using the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. 
The baseline phenotype information included gender, age, and an array 
 
Journal of Psychiatry and Brain Science 5 of 16 
 
J Psychiatry Brain Sci. 2019;4:e190003. https://doi.org/10.20900/jpbs.20190003 
 
of clinical phenotypes reflecting different symptom dimensions. Here, we 
investigated the associations between PRSs and the GAF score. For the 
GAF, we additionally adjusted for the total PANSS score that summarizes 
all PANSS subscales. After excluding missing data, we retained a subset of 
653 patients with baseline information of GAF score, PANSS, age (in 
years), and gender. To perform PRS analyses, we downloaded the single 
SNP summary statistics data set of 102,636 already clumped SNPs, based 
on the discovery sample of 36,989 cases and 113,075 controls from the 
PGC website. We identified all SNPs in common between these PGC data 
and our PsyCourse imputed data. This resulted in 93,471 SNPs to be used 
to investigate the association between SZ-PRS and the target trait in the 
target sample.  
Simulated Data 
Our simulation comprised three main parts: (1) generation of 
genotype data (independent of phenotypes); (2) simulation of phenotypes 
for the discovery and target trait (T1) via an additive heritability model; 
and (3) generation of additional target phenotypes (T2, T3, and T4) which 
are correlated to T1 and thus also to the discovery trait. As the discovery 
sample of the PGC study comprised approx. 34,000 schizophrenia cases 
with European ancestry [5,6], we chose this sample size for the discovery 
trait in our simulations. Sample sizes for the target traits were set as n = 
200, 500, and 1000. We selected these sample sizes in a context that 
phenotyping for the target trait might prove quite challenging. We 
simulated 50,000markers of which nc = 20 are causal markers shared 
between the discovery trait and all target traits.  
Genotype Simulation 
Employing Hapgen 2.0 (http://mathgen.stats.ox.ac.uk/genetics_software/ 
hapgen/hapgen2), we simulated 50,000 markers for 34,000 individuals 
based on the European HapMap reference population of Utah Residents 
with Northern and Western European Ancestry (CEPH-CEU), keeping the 
LD pattern. Hapgen 2.0 required us to assign case-control status; however, 
we simulated a null model in which none of the genotypes carries any 
effect on the case-control status. We then sampled 100 replicates of 
genotypes for the target traits from these 34,000 individuals in samples of 
n = 200, 500, and 1000 with replacement.  
Phenotype Simulation 
We simulated the phenotypic values for the discovery trait and for T1 
under an additive SNP heritability model. In this additive model, the 
phenotype Yi of each individual, i = 1,…,n is modelled as the sum of linear 
effects of the causal SNPs j = 1,…,nc and an error term εi. In the generation 
model, the nc = 20 causal markers explain approximately 80% of the 
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additive SNP heritability h2, while the remaining markers in the panel 
explain less than 1% heritability.  
i i j j i
j
Y Z β ε= +  
Here βj denotes the additive genetic effect of the j-th causal SNPj, Zij is 
the ij-th element of the genotype matrix, standardized for SNP 
frequencies, such that xij denotes the number of reference alleles of the  
j-th causal variant in individual i and fj the corresponding population 











The error term εi  follows a normal distribution with mean zero, 
where the total variance σ2ε is controlled by the desired total additive 
heritability of the trait h2. h2 is the sum of the additive heritabilities for 
each individual SNPj, h2j, determined by allele frequency and effect size 
as follows: h2j = 2β2j × fj (1 − fj) .  
2
2
1var( ) ( )(1 )ij jj
Z hεσ β= ⋅ −  
Employing this model, we generated the values of the discovery 
phenotype for 34,000 individuals of the discovery sample as well as the 
values of the target phenotype T1 for the individuals of the much smaller 
target samples. Additionally, we simulated normally distributed target 
traits T2, T3, and T4 with correlation r = 0.8, 0.6, and 0.4, respectively, with 
T1 and thus with the discovery trait. Here we took into account the 
geometric property that for any two vectors with mean 0 the correlation 
r between them equals the cosine of the angle [16]. 
Statistical Analyses 
PsyCourse data 
Our primary statistical analysis investigated how well the 
schizophrenia-based PRS can explain baseline symptom severity (GAF score) 
for all individuals. Prior to the PRS analyses, we assessed the difference in 
means of both diagnostic groups for GAF, PANSS age, and gender, using  
t-test, Mann-Whitney U Test and chi-squared test as appropriate. 
For each individual in the target sample (n = 653) and for each of the 
93,471 SNPs in common with the PGC data, the sum of dosages for risk 
alleles (0, 1, and 2) was multiplied by the log OR for that particular 
variant estimated by the PGC study [5]. The resulting values were 
summed up in an additive fashion in the order of p-value ranking in the 
PGC study. Thus an individual estimate of the SZ-PRS was obtained at 106 
different p-value thresholds (pt  ≤  5 × 108; pt  ≤  0.0001; pt  ≤  0.001; pt  ≤  
0.01 to pt  ≤  1.00 by increments of 0.01).  
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We performed four regression models to estimate the explained 
variance for GAF. In the first model (M1) we only included age, gender, 
and PCs as the set of potential confounders (SPC). In the second model 
(M2), we added SZ-PRS into M1. It is well known that the symptom scales 
GAF and PANSS are highly correlated [16]. Thus, in the third model (M3) 
we added PANSS to M1 and in the fourth model (M4) we added SZ-PRS to 
M3. We considered GAF a continuous normally distributed variable as an 
approximation to the ordinal scale. We analysed these four models in all 
patients and separately in the psychotic and affective patients to 
elucidate whether potential effects of baseline severity are restricted to 
one of these groups or are a more general phenomenon. M2 and M4 were 
performed separately using each of 106 SZ-PRSs estimated at 106  
p-values; we only report the results for the model obtained at po 
Simulated data 
Owing to the presence of LD between genetic markers in the 
simulated data, we performed LD clumping prior to computing PRS using 
a threshold of r2 = 0.2 for all SNPs within a window of 250 kbp. Clumping 
yielded 7432 SNPs that essentially included causal SNPs (nc = 20). We then 
used the weights from the summary statistics of our discovery trait for the 
clumped SNP set to calculate the PRS in the target trait samples. We used  
p-value thresholds ranging from 0.01 up to 0.5 at increments of 0.01. 
In all sample sizes, we considered the distribution of the “variance of 
the target trait explained by the regression using the PRS”, i.e., R2, and 
optimal p-value thresholds across replicates. We reported the mean, 
standard deviation, and range of R2 across the 100 replicates. We also 
reported the optimal p-value thresholds (p0) of each replicate for the 
correlated traits (T1–T4) as well as the number of markers employed by 
PRS at p0, across replicates. 
All the PRS calculations for the PsyCourse and simulated data were 
computed in PLINK 1.90 (https://www.cog-genomics.org/plink/1.9) and for 
further statistical analyses as well as data handling we used R, version 
3.2.0 (https://www.r-project.org/).  
RESULTS 
PsyCourse Data 
Using the baseline visit information of the PsyCourse data [14], we 
identified n = 653 individuals (57.9% males) who were diagnosed into the 
two broad categories psychotic and affective. There were n = 387 
psychotic patients (8.3% are FEP; 62.3% males) and n = 266 affective 
patients (9.8% FEP, 51.5% males). The more specific diagnoses according 
to DSM-IV criteria within each of these groups were as follows: Of the  
n = 387 psychotic patients 80.1% were SZ patients, 16.5% schizoaffective 
disorder patients, 2.1% schizophreniform disorder patients and 1.3% 
brief psychotic disorder patients. Of the n = 266 affective patients 82.0% 
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patients had bipolar-I disorder and 18.0% patients bipolar-II disorder. 
Table 1 provides an overview of the mean and standard deviation for 
GAF, PANSS, age and gender for all patients and the two main diagnostic 
groups. We additionally computed 95% confidence intervals (95% CI) for 
the difference in means between the diagnostic groups and tested 
whether the means were different. All variables show difference 
between the two diagnostic groups. 
Table 1. Comparison of GAF, PANSS, age, and gender between the two diagnostic groups.  
Diagnostic Group 
Scale 
All (n = 653) Psychotic 
(n = 387) 
Affective 
(n = 266) 
Difference between 
subgroups  
Mean (SD) p-value 95% CI 
GAF 57.5(13.4) 54.5(13.5) 61.9(11.9) 3.6 × 10−13 5.5, 9.4 
PANSS 52.6(19.2) 59.6(20.7) 42.4(10.6) 2.2 × 10−16 −19.6, −14.7 * 
Age 42.8(13.0) 40.4(12.3) 46.2(13.3) 2. 5 × 10−8 3.8,7.8 
Gender(M) 57.8% 62.2% 54.8% 0.007857 1.11, 2.15 
* 95%CI according to normal distribution, but a non-parametric test was used. 
We considered four regression models with GAF as outcome and SZ-
PRS, PANSS, and 5 PCs as input variables for all patients and stratified for 
the two diagnostic groups. As the scree plot revealed no clear cut-off beyond 
including two PCs, we investigated including two up to ten PCs. The fifth PC 
explained more variance in GAF than others. Thus this appears to be the 
optimal choice, as well as yielding the largest increase in R2. 
Table 2 lists the estimated R2 along with the corresponding p-value of 
the model. Note that the optimal p-value threshold value p0 = 0.0001 for 
models M2 and M4 is selected from a series of regression models using the 
SZ-PRS estimates calculated at 106 different p-value thresholds. The 
maximum increase in R2 from M1 to M2 was 0.49% and 0.90% from M3 to 
M4. Note that the latter corresponded to a regression coefficient for PRS 
in M4 of 2.45 (95% CI = (−0.13, 5.03), p-value = 0.063). 
Table 2. Results for estimated R2 and model p-value for the four regression models M1–M4 for all patients 
and stratified by diagnostic group.  
Model All Psychotic Affective
R2 p-value R2 p-value R2 p-value
M1 0.040 3.17 × 10−4 0.052 4.37 × 10−3 0.043 0.011
M2 0.045 1.68 × 10−6 0.063 1.47 × 10−5 0.049 0.115
M3 0.372 1.80 × 10−61 0.350 4.10 × 10−32 0.340 3.75 × 10−20
M4 0.381 2.41 × 10−61 0.360 3.40 × 10−32 0.350 9.12 × 10−20
All p-values are FDR corrected. 
 
Journal of Psychiatry and Brain Science 9 of 16 
 
J Psychiatry Brain Sci. 2019;4:e190003. https://doi.org/10.20900/jpbs.20190003 
 
Simulated Data 
Using the summary statistics obtained from the GWAS on the 
discovery trait, we determined PRSs for the respective target samples of  
n = 200, 500, and 1000 in 100 replicates. For our PRS analyses we reported 
the mean, standard deviation (SD), and range of estimated R2 when 
regressing on T1, T2, T3, and T4, respectively, on PRS at the optimal p-value 
threshold p0 (see Table 3).  
Table 3. Summary of the estimated R2 by PRS in target traits T1–T4 for all sample sizes across 100 replicates. 
R2 n = 200 n = 500 n = 1000 
Mean (SD) Range Mean (SD) Range Mean (SD) Range 
T1 0.32(0.08) 0.13–0.54 0.33(0.07) 0.17–0.47 0.33(0.07) 0.17–0.49 
T2 0.21(0.06) 0.06–0.37 0.21(0.05) 0.09–0.32 0.21(0.04) 0.11–0.33 
T3 0.13(0.04) 0.03–0.28 0.12(0.03) 0.03–0.20 0.12(0.02) 0.06–0.19 
T4 0.05(0.02) 0.006–0.16 0.05(0.02) 0.006–0.10 0.05(0.015) 0.02–0.09 
In all analyzed sample sizes, the average value of R2 estimated by PRS 
for T1 was approximately 32%, where T1 followed exactly the same 
generation model as the discovery trait. For the phenotypes T2, T3, and T4, 
correlated with T1, a decreasing R2 was observed with decreasing 
correlation, for T2 on average 21%, for T3 12%, and for T4 5%, respectively. 
Note also that the average R2 estimates for the optimal PRS model were 
stable in each target trait while SD decreased and the range increased 
with decreasing sample size, as expected.  
Overall, R2 estimated by the PRSs for 100 replicates were 
approximately normally distributed, as expected (data not shown). For 
the final PRSs of all replicates Figure 1 displays boxplots of R2 (Figure 1a), 
of the optimal p-value thresholds (Figure 1b) and of the total number of 
SNPs included in these final PRSs (Figure 1c). While median R2 and 
interquartile boxes are quite comparable between sample sizes, Figure 1a 
reveals that for the small sample sizes some outliers at high R2 values can 
be observed. The degree of variance explained declines dramatically 
with decreasing correlation with the discovery trait. In Figure 1b, no 
outliers are seen in the distribution of optimal p-value thresholds. 
However, the interquartile boxes are very large, showing how highly 
variable the selected threshold is. As the sample size decreases, the 
optimal p-value threshold decreases. It decreases dramatically from  
n = 500 to n = 200 for T1, and less dramatically for traits correlating to a 
lesser extent with the discovery trait. The average number of SNPs 
included into the final PRS, i.e., the one at p0, ranged from 2400 to 6400 
across all traits. However, a number at the high end of these ranges is 
much more likely for T1 and several outliers at the low end are displayed 
at all sample sizes. The drop in the interquartile box for T4 at the lowest 
sample size is remarkable.  
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Figure 1. (a) presents the R2 plot, (b) displays the optimal p-value threshold (po) and (c) illustrates the 
number of SNPs in the PRS model at the po for all the sample sizes for all the target traits (y-axes:T1–T4) 
across 100 replicates of PRS analyses. Within each boxplot, the solid vertical line signifies the upper 
quantile and lower quantiles and the median is represented by a short horizontal black line. 
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With an identical generation model for both discovery trait and T1, 
our simulation results reveal that PRS explain on average 32% variance 
of T1. Thus, out of a total of 80% trait heritability for T1, 40% of 
heritability is explained by the PRS. For a trait heritability of 80% with 
99.99% null markers (nc = 1000/1000000) in the model, previous 
simulation studies [1] demonstrated that a sample size of n = 31,000 is 
needed to achieve the maximum R2 ~80% for both target and discovery 
trait. Thus, this number is sufficiently large to shrink observed effect 
sizes for a sufficient proportion of null markers below noise level. Our 
discovery trait exceeds the required sample size, i.e., 34,000. However, in 
the situation of difficult-to-phenotype our target trait sample sizes are 
necessarily much smaller (n = 200, 500, 1000). As the set of causal 
markers is also identical between the discovery trait and T1, we can even 
speak of a common genetic etiology in this sense or it may be assumed as 
the same trait for both discovery and target sample. Although it is not 
possible to separate the PRSs estimated on multiple p-value thresholds 
for the causal and non-causal set of markers, it is essentially a sum of two 
PRSs i.e., PRS = Pcausal + Pnon-causal; here Pcausal is the PRS estimated using 
causal markers and Pnon-causal is the PRS estimated using non-causal 
markers. Thus, adding non-causal SNPs in the PRS will lead to a 
substantial increase in mean squared error of the regression model and 
thus decrease the R2 estimate. Employing the same phenotype generation 
model both for discovery and T1, the population correlation between 
them is equal to one, and given 80% heritability, the maximum 
correlation between PRS and T1 should be r = 0.89. In the target sample, 
the exact empirical correlation between T1 with the discovery trait is 
unknown, whereas the correlation between T1 and PRS is estimated on 
average as r = 0.32  = 0.56.  
For the correlated traits T2–T4, the mean R2 roughly decreases by the 
square of the correlation between T1 and the corresponding trait. Thus, 
from T1 (R2 = 0.32), the mean R2 estimates decrease for T2 to R2 = 0.82 × 
0.32 = 0.21, for T3 to R2 = 0.62 × 0.32 = 0.12, and for T4 to R2 = 0.42 × 0.32 = 
0.05. This gradual decrease in mean R2 estimates from T1 to T4 
corresponds well with decreasing empirical correlation among target 
traits. However, the range of R2 increases with decreasing sample size, 
more outliers appearing with smaller sample sizes. Similar to T1 for 
correlated traits, the average R2 estimates remains stable across all 
sample sizes.  
PsyCourse Data 
In the PsyCourse data with GAF as an outcome, we also dealt with 
different sample sizes, as we considered all patients and stratified 
analyses by the two diagnostic subgroups. When adjusting for age, 
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gender, and 5PCs, SZ-PRS (M2) does not contribute much to the variance 
of GAF. GAF and PANSS are negatively correlated with each other 
approximately r = −0.40 [17], and a similar estimates in our data. Thus, a 
regression model (M3) including confounders and PANSS for acute 
symptoms explains a much greater proportion of the variance in GAF. 
Beyond PANSS and confounders, SZ-PRS explains 1% additional variance 
(M4). This holds true for all patients and in the diagnostic groups. Note 
that, despite a small R2, the regression model M2 including SZ-PRS and 
confounders was significant for all patients and the larger psychotic 
group and not significant for the smaller affective group. It is thus hard 
to argue that the GAF score reflects symptom severity in the psychotic 
group only.  
As stated above, the regression coefficient for PRS in M4 is 2.45 (95% CI 
= (−0.13, −5.03), p-value = 0.063), yielding an increase in R2 of 0.90% over 
the model without PRS. We investigated this result further for robustness 
with respect to the number of PCs included or influential patients for this 
regression. The estimate of the regression coefficient decreased slightly 
with adding more PCs, the width of the confidence interval remained 
stable, albeit shifting more to the right (that is more towards significance). 
We identified two influential patients (leverage points) with high GAF 
values and slightly low PRS, without any indication that these patients 
should be excluded. However, if excluded, the increase in R2 when 
including SZ-PRS would only be 0.5%. Taking all these points together, 
the result by itself needs to be validated in a larger study before it can be 
considered for risk modelling or prediction.  
As also shown in the simulation, we possibly retrieve only a small 
proportion of the true R2 in small to moderate sample sizes, as typical for 
some clinical trials with longitudinal elements or complicated imaging 
measures. With very large studies also available for the target trait, 
Dudbridge’ study [1] demonstrates good retrieval of various higher R2. 
A clinical application requires that the SZ-PRS yields a higher 
proportion of variance explained when added to models including 
clinical scales such as the PANSS. However, this is not sufficient. These 
results are in agreement with those found for several psychological traits 
(retrieving <3% of variance by SZ-PRS) [18]. The hope is that multiple 
molecular and non-molecular scores (such as the PRS) might aid in 
identifying individuals at risk of disease or disease progression. This will 
only be possible if a much larger proportion of variance is explained in 
total, either for heterogeneous patient groups or for much more 
homogeneous groups possibly also identified by PRS. 
As GAF follows an ordinal scale of number of symptoms, some 
authors argue for the use of a Poisson distribution as used in the FEP 
study [8]; thus we checked the robustness of our results employing 
Poisson regression in the four regression models. These qualitatively 
yielded the same results (not shown). Additionally, we repeated our 
regression analyses for all models by performing p-value-informed 
 
Journal of Psychiatry and Brain Science 13 of 16 
 
J Psychiatry Brain Sci. 2019;4:e190003. https://doi.org/10.20900/jpbs.20190003 
 
clumping on the PsyCourse dataset, which almost tripled the number of 
SNPs (from 93,471 to 275,719) in the SZ-PRS SNP set. We observed that the 
models incorporating PRS constructed with pre-clumped SNP data 
explained more of the variance in GAF. However, it should be noted here 
that the regression coefficients for SZ-PRS derived both from pre-clumped 
and p-value-informed clumped SNP sets were insignificant. 
Integration of Simulation Study and PsyCourse Data 
The three sample sizes of PsyCourse we analysed were n = 266, 386 
and 653. These can be regarded in light of the sample size effects in our 
simulations of n = 200, 500 and 1000 individuals. Only a very minor 
percentage of variance for GAF was explained by SZ-PRS, so this most 
likely resembles a scenario of moderate to low correlation between SZ as 
the discovery trait and GAF as the target trait. This seems plausible as 
correlation between PANSS and GAF [17] is similar to our target trait T4.  
In Santoro and Sengupta et al.’s studies [8,9], SZ-PRS was employed to 
measure its association with GAF in FEP patients only. In Santoro et al.’s 
study [8], for n = 50 FEP patients, the association between GAF and SZ-
PRS (p0 = 0.0112) was estimated in a Poisson regression framework and 
the model was adjusted for the 4 PCs. However, the reported results are 
significant (GAF; p = 0.003), an R2 is not given. Our model with SZ-PRS and 
confounders as input is comparable to the model in Santoro et al.’s study 
[8] and our results are significant as well, with a small R2 as stated 
previously. Another study [9] also reported the estimates of correlation 
between SZ-PRS (using only the significant 108 loci reported by PGC [6]) 
and GAF for n = 241 FEP individuals, but they reported no significant 
association (p = 0.801). Thus the contribution of mutual genetic variants 
to the genetic burden of GAF is not evident.  
Our simulations revealed that in general, with decreasing correlation 
between target traits, the simulated trait heritability is also decreasing as 
a function of squared correlation between respective target trait and T1 
times mean R2 of corresponding trait. Additionally we observed that with 
smaller sample sizes, the underlying distribution of R2 across 100 
replicates had more outliers towards larger R2 values by chance as 
compare to that of larger sample size. Therefore it is critical to consider 
the correlation between discovery and target trait in general as well as to 
carefully interpret results with smaller sample size such as the n = 266 
individuals for the affective group. 
The distribution of optimal p-value thresholds for T1 is narrower for 
larger sample sizes than for smaller ones. The best R2 also occurs at 
higher p-values thresholds, indicating that more markers are included 
into the final PRS. For all sample sizes from T1 to T4, the tails of optimal  
p-value threshold distributions become wider in both directions, 
indicating increasing instability in optimal p-value thresholds with 
decreasing correlation in target traits. In a simulation study [19] with 
varying sample sizes and employing various trait heritabilities, the 
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optimal p-value thresholds decreased with sample size. Lower thresholds 
indicate inclusion of fewer markers in the model that is reflected with 
decreasing correlation in the target traits as well. In the PsyCourse 
analysis of GAF with PRS however, we observed a consistently optimal  
p-value threshold regardless of varying sample sizes of n = 266, 387, and 
653.  
CONCLUSION  
In this study we performed simulations considering rather realistic 
sample sizes for the PRS analyses in the setting in which a large-scale 
GWAS on 34,000 individuals is available for the discovery trait and the 
sample size of the target trait is limited and cannot reach several 
thousand individuals, for example in the context of clinical trials. We 
also assessed the performance of PRS in phenotypes with varying 
correlations. Our simulations with identical causal markers between 
discovery and target trait reveal that reduced correlation of a phenotype 
with the discovery trait considerably reduces the effect sizes of shared 
polygenic components between target and discovery trait; this effect may 
be magnified if causal markers only overlap partially.  
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